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 The cell cycle is a tightly regulated series of molecular events which dictates 
proliferation. Both the timely activation of genes through transcription and destruction of 
proteins through the ubiquitin-proteasome system are integral to normal cell cycles. 
Dysregulation of these networks often underlie a variety of malignant diseases such as cancer. 
 Forkhead box protein M1 (FOXM1) is an essential cell cycle transcription factor. 
FOXM1 regulates a transcriptional network that controls the G2/M transition and G1/S transition. 
Additionally, aberrant upregulation of the FOXM1 transcriptional network is linked to a variety 
of cancers. The kinases which activate FOXM1 are well explored, but the influence of the 
ubiquitin-proteasome system on FOXM1 remains unclear. Here, I described the role that two 
such enzymes, the E3 ubiquitin ligase CUL4-VPRBP and the deubiquitinating enzyme (DUB) 
USP21, have on the stability and activity of FOXM1 in both normal and dysregulated cell cycles. 
 First, I demonstrate that FOXM1 degradation is enhanced by association with CUL4-
VPRBP. Depletion of VPRBP enhances FOXM1 stability and causes mitotic entry defects. 
Interestingly, overexpression of VPRBP enhances both FOXM1 ubiquitination and 
transcriptional activity by a process that occurs independent of CUL4. Finally, VPRBP and 
FOXM1 levels are assessed in high-grade serous ovarian cancer (HGSOC) patient tumors, 
demonstrating a plausible mechanism for FOXM1 activation. 
 iv 
 Second, I demonstrate that FOXM1 is protected from degradation through association 
with the DUB USP21. Knockdown or overexpression of USP21 is able to destabilize or stabilize 
FOXM1, respectively, through deubiquitination of FOXM1. USP21 is able to influence mitotic 
entry and proliferation through regulating the FOXM1 transcriptional network. Furthermore, 
USP21 and FOXM1 are both significantly amplified in basal-like breast cancer with the 
knockdown of both sensitizing cells to the chemotherapy paclitaxel thus describing a novel 
combination treatment for this disease. 
 Taken together, these results contribute to our understanding of how the ubiquitin-
proteasome system positively and negatively regulates the abundance and activity of FOXM1. 
The research presented here further extends our understanding of the network of interactions 
regulating normal cell cycle dynamics and provide mechanistic and novel therapeutic insights 
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CHAPTER 1: INTRODUCTION 
The Ubiquitin-Proteasome System 
Background 
 The ubiquitin-proteasome system (UPS) will play an important role in the work described 
in the subsequent chapters. As such, I would like to give a cursory overview of the history, 
mechanisms and general functions of the UPS in this section (Figure 1.1). A more thorough 
explanation of E3 ubiquitin ligases and cullin-RING ligase 4 will be described as they are 
importantly involved in the studies described in Chapter 2. Similarly, deubiquitinating enzymes 
and ubiquitin specific protease 21 (USP21) will be described in more detail as they are central to 
the studies described in Chapter 3. 
The UPS describes a network of proteases which influence the abundance, stability and 
function of the vast majority of the proteins within the cell. It was long believed that most 
cellular proteins were stable and long-lived. It wasn’t until work done in the late 1970’s and 
early 1980’s that this paradigm began to shift. Hershko, Ciechanover and Rose elegantly 
demonstrated that proteins added to a reticulocyte extract can become covalently conjugated to a 
small protein called ubiquitin (1, 2). Furthermore, they discovered that these proteins conjugated 
to ubiquitin are subsequently destroyed by an ATP-dependent protease, later described as the 
26S proteasome, in the extract (3–5). Due to the broad influence of the UPS on nearly all of the 
cells major signaling pathways, efforts continue to fully identify and understand links between 
enzymes of the UPS, specific substrates and how these interactions regulate essential cell 
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processes, how their dysregulation can lead to disease and how we may be able to leverage the 
UPS for therapeutic effect (6–9). 
Enzymes of the Ubiquitin-Proteasome System 
 The signal by which this system communicates occurs through the conjugation of 
ubiquitin, a small 8.6 kDa regulatory protein, to the lysine’s (or methionine in N-terminal 
ubiquitin-ubiquitin linkages) of other proteins. This process is orchestrated by a cascade of 
enzymes described as E1 (ubiquitin-activating enzymes), E2 (ubiquitin-conjugating enzymes) 
and E3 (ubiquitin ligases) (10). The process of conjugating ubiquitin onto the lysine of a protein 
begins when the E1 enzyme generates a high-energy thiol ester intermediate with ubiquitin in a 
reaction requiring ATP (E1-S-ubiquitin) (11). From here, one of several E2 enzymes participates 
in a reaction with the E1-S-ubiquitin intermediate in which the ubiquitin is transferred in a thiol 
ester reaction to the E2 enzyme (E2-S-ubiquitin) (12). At this point, E2 enzymes bind into a 
complex with E3 ubiquitin ligase enzymes which also engage the substrate that is to be 
ubiquitinated (10, 13). By keeping the substrate and the E2 enzyme conjugated to ubiquitin close 
to one another, the E3 ubiquitin ligases facilitate the transfer of ubiquitin onto the substrate. In 
this reaction, the C-terminal glycine of ubiquitin forms an amide linkage with the side chain of a 
lysine residue on the protein being ubiquitinated (14). This reaction can occur once, where only 
one ubiquitin is placed onto a substrate (monoubiquitination) (15), multiple times where a 
ubiquitin is added to a different lysine than the first (multi-monoubiquitination) or multiple times 
where ubiquitin is conjugated on to the lysines of the first ubiquitin conjugated onto the protein 
(polyubiquitination) (10).  
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Additionally, there is a class on enzymes known as deubiquitinating enzymes (DUBs) 
which antagonize this reaction and are able to bind substrates and remove ubiquitin directly from 
the protein itself or remove or edit polyubiquitin linkages (16). The specific ubiquitin code 
remaining on substrate proteins following interaction with the enzymes of the ubiquitin-
proteasome system can have a variety of functional or signaling outcomes (10, 15).  
One outcome of ubiquitin signaling, which is closely linked with polyubiquitin chain 
formation, is degradation. This occurs when ubiquitinated proteins interact with the 26S 
proteasome where they are digested into their component amino acids and the ubiquitin is 
recycled (10). Finally, there are a number of ubiquitin binding proteins (UBPs) within the cell 
which are able to bind and recognize the ubiquitin modifications on target proteins and determine 
downstream signaling outcomes for these ubiquitinated proteins (17). 
E3 Ubiquitin Ligases 
With around six hundred E3s encoded in the human genome (compared to two E1s and 
around fifty E2s), the E3 ubiquitin ligases represent the largest and most diverse set of enzymes 
within the broader family of enzymes comprising the ubiquitin-proteasome system (18). Due to 
this large number and the fact that E3 ubiquitin ligases are the enzymes which directly recognize 
unique substrates, most of the specificity in ubiquitin signaling is conferred through E3 ubiquitin 
ligase-substrate interactions. As such, the linking of specific substrates to their cognate E3 
ubiquitin ligases remains of great interest for understanding how and which cell signaling 
pathways are influenced by the ubiquitin-proteasome system. 
Much is known about the molecular mechanisms regulating E3 ubiquitin ligase formation 
and activity. Broadly, E3 ubiquitin ligases are separated into two major classes based on 
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sequence and function. These are the RING (really interesting new gene)-domain E3s and the 
HECT (homologous to the E6AP carboxyl terminus)-domain E3s. The RING-domain E3 
ubiquitin ligases are the largest of the two groups with around 300 RING-containing genes 
encoded by the human genome (18). In some RING-domain E3 ligases the substrate recognition 
site and the catalytic site is found within the same polypeptide, but for the vast majority of 
RING-domain E3 ligases, the substrate recognition module and the catalytic subunit are 
separated into distinct polypeptides which come together to form a multi-subunit complex. More 
specifically, there are over two hundred modular cullin-RING ligases (CRLs) which can be 
formed from the combination of RING-domain containing proteins with a rigid cullin protein 
scaffold (19). The human genome encodes eight different cullins (CUL1, 2, 3, 4A, 4B, 5, 7 and 
9), each of which engage a distinct set of subunits which are often referred to by various names 
(19). When fully assembled, E2-E3 CRLs are able to engage with substrates and participate in 
reactions that both initiate the addition of ubiquitin on a target substrate or elongate ubiquitin 
chains on a target substrate which result in substrates which are competent for subsequent 
degradation by the proteasome (20). 
In addition to assembly dynamics, CRLs are regulated by the addition of a small, 
ubiquitin-like modification on the cullin scaffold known as NEDD8. The addition of NEDD8 to 
the cullin changes the conformation of the complex and allows for the E2 to be brought into 
closer proximity to the substrate being held by the E3 (21). This allows for the transfer of 
ubiquitin on to the substrate. Much like ubiquitin conjugation, the conjugation of NEDD8 is a 
reversible reaction and can be removed by the COP9 signalsome (CSN) (22). CSN deconjugation 
of NEDD8 is inhibited when a CRL complex is fully assembled with substrate attached but is 
able to remove NEDD8 following CRL disengagement with substrate. In this way, CRLs are 
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able to be reset to a deNEDDylated state to engage new substrates but their activity is not 
compromised when they are indeed bound to substrate.  
Additionally, there is another regulator of CRL complex formation known as CAND1. 
When CRLs are deNEDDylated, CAND1 can bind to the cullin scaffold and compete for binding 
directly with the E3 (23). When CAND1 predominates, this can block E3 binding and inhibits 
the cullin scaffold from engaging with other E3 partners. However, the addition of NEDD8 
blocks the binding of CAND1 to the cullin scaffold and shifts the balance towards productive, 
fully assembled CRL complexes. This interplay between CAND1, E3s and NEDD8 is essential 
for the dynamic switching of E3s (24). 
CRL4A and CRL4B 
 Of all the cullins, CUL4 is the only one which exists as a subfamily including 2 members, 
CUL4A and CUL4B which share over 80% sequence identity and functional redundancy (25). 
CUL4A and CUL4B engage with DNA damage binding protein 1 (DDB1) and CUL4-associated 
factors (DCAFs) to form active complexes (26, 27). CUL4A and CUL4B display differential 
expression based on tissue type with high expression observed in the thymus, testis, ovaries, T 
cells, multiple blood types as well as skeletal muscle (28). CRL4 promotes the ubiquitination of 
a number of substrates, both known (29) and predicted (27) involved in a range of physiological 
processes including DNA damage repair, chromatin remodeling, cell cycle progression, 
embryogenesis, hematopoiesis and spermatogenesis (29). CRL4 has been closely linked to a 
number of diseases. In cancer, it was discovered that CUL4A overexpression is a common 
feature of many breast cancers with its genomic loci, 13q34, being amplified in many p53-
deficient, BRCA1 deficient and basal-like breast cancers (30–32). Hepatitis B virus (33, 34), 
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Simian Virus 5 (35) and human immunodeficiency virus (HIV) (36) encode accessory proteins 
which are able to bind and engage CRL4 to degrade host proteins such as STAT1 (37), UNG2 
(38, 39) and SAMHD1 (40–42). Intriguingly, HIV Vpr is able to engage CRL4 through 
interaction with DCAF1/VPRBP which is sufficient to promote a G2 arrest and apoptosis (43–47) 
though the exact mechanism which promotes this arrest phenotype remains elusive. 
Understanding the exact targets which exert this G2 arrest remains of great interesting in the 
field. Additionally, it has been discovered through genetic analysis of families who suffer from 
X-linked intellectual disabilities that mutations in the CUL4B gene are highly prevalent (48). 
More work remains to thoroughly validate and categorize specific CUL4 substrates and will 
significantly contribute to our understanding of cellular process which depend on CUL4 and how 
CUL4 dysregulation contributes to diseases.  
DUBs 
 Currently, there are 99 identified DUBs which can be further categorized into two 
broader functional groups and seven separate subfamilies based on their mechanism of action 
with respect to catalytic activity and other features (16). The larger of the two groups are the 
cysteine protease DUBs, which depend on a catalytically active triad or diad of amino acids, 
including cysteine, to catalyze the removal of ubiquitin from cognate substrates. Six of the seven 
families of DUBs (ubiquitin-specific proteases (USPs), ubiquitin C-terminal hydrolase (UCHs), 
ovarian tumor proteases (OTUs), Machado-Josephin domain proteases (MJDs), motif interacting 
with Ub-containing novel DUB family (MINDYs) and ZUP1) are cysteine protease DUBs. The 
smaller of the two functional groups are the metalloprotease DUBs, in which the catalytically 
active residues coordinate a zinc ion which is important for ubiquitin cleavage (49). The seventh 
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family, the Jab1/Mov34/Mpr1 Pad1 N-terminal+ (JAMM/MPN+) domain proteases (49–51), fall 
under this functional category. 
 DUBs can cleave the isopeptide bonds between ubiquitin molecules and modified 
proteins or the isopeptide bond which links ubiquitin molecules together in chains. There are a 
wide variety of other preferences which influence the specificity of DUB activity (52). Some 
examples of these specific preferences include: chain linkage type (i.e. K11 versus K48 versus 
K63 linkage) (53), end processing (distal-end versus inter-chain) (16, 53), chain length (54–56), 
number of ubiquitin molecules removed (monoubiquitin versus en bloc chain removal) (49, 57)  
and substrate recognition (58). Some DUBs can also remove small ubiquitin-like modifications 
such as SUMO (59), ISG15 (60) and NEDD8 (61). Abundance and localization of DUBs varies 
greatly and heavily influences the cellular processes which they regulate (62–64).  
Much like E3 ubiquitin ligases, pairing DUBs with their substrates and the process with 
which they exert influence is important to informing our understanding of the biology of DUB 
behavior (58). Also, DUBs have the potential to make excellent therapeutic targets due to their 
influence over specific cell signaling pathways and their biochemical properties (16). Linking 
DUBs to specific disease conditions and generating potent and selective DUB inhibitors has 
great therapeutic potential and should be the focus of future studies (65). In contrast to the 
ubiquitin ligases, the study of DUBs is far less mature. Comparatively less is known about the 
molecular mechanisms which regulate their activity or substrate binding preferences. These are 
open questions which will be addressed as the field continues to mature over the coming years. 
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USP21 
 Ubiquitin specific peptidase 21 (USP21) is a 565 amino acid member of the USP family 
of DUBs. The USP21 gene is mapped to chromosome 1q23 (66). USP21 was first cloned from a 
human placenta cDNA library and was demonstrated to have the ability to remove both ubiquitin 
and NEDD8 conjugates (67), though reports on NEDD8 deconjugation remain mixed (68, 69). 
Like many USP family DUBs, USP21 utilizes a catalytically active triad of cysteine, histidine 
and asparagine to cleave ubiquitin isopeptide bonds. USP21 has been crystalized in complex 
with a linear di-ubiquitin probe where it adopts a “finger, palm, thumb” conformation around 
ubiquitin chains (68). The C-terminal domain extends out and interacts with the distal end of the 
ubiquitin molecule and the catalytically active site wraps around the ubiquitin isopeptide bond in 
a conformation similar to the region between the palm and thumb of a hand when gripping a 
handle (68). 
 USP21 primarily displays a nuclear localization, but does contain a nuclear export 
sequence (70) and has been demonstrated to regulate centrosome and microtubule-associated 
functions (71) as well as the MARK family of kinases (58, 72). However, most of the identified 
USP21 substrates exist within the nucleus. USP21 influences general transcription through the 
removal of ubiquitin on histone H2A K119 (73) and EZH2 (74). USP21 also influences 
transcription more acutely through influence the stability of a variety of transcription factors 
such as GATA3 (75), GLI1 (76), NANOG (77). It has also been demonstrated that USP21 can 
bind to the promoter region of IL-8 and aid in its transcriptional initiation (78). USP21 has also 
been implicated in host immune response through interaction and deubiquitination of RIP1 (79), 
RIG-I (80) and IL-33 (81) together with the stimulation of interferon genes following viral 
infection (82) and through the preventing the generation of FOXP3+ regulatory T cells through 
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stabilizing FOXP3 (83). Recently, USP21 has also been implicated in DNA damage repair 
through the stabilization of BRCA2 (84). USP21 expression is linked to cell proliferation with 
knockdown of USP21 slowing cell growth and tumor formation with USP21 overexpression 
enhancing growth and tumor formation (67, 74).  
Intriguingly, the genomic loci of USP21 (1q23) is often amplified in a variety of cancers, 
though the exact oncogenes or reasons why this region seems to be preferentially selected for in 
cancers remains unclear (85). The exact mechanisms which regulate the activity of USP21 
remain elusive. Future work describing how and when USP21 is activated and additional 
substrates it engages will greatly add to our knowledge of how USP21 broadly influences cell 
signaling pathways and how USP21 may contribute to the progression of disease. 
 
The Cell Cycle 
Historical Background  
 The cell cycle describes a series of events which regulate the process by which cells 
reproduce. This is an evolutionarily conserved process which is conserved in all living organisms 
from unicellular microorganisms to plants to man which ensures growth, differentiation and the 
transmission of genetic material from one cell to the next generation. The earliest description of 
what could be considered the theory of the cell cycle dates back to the late nineteenth century 
when a number of biologists studying early developmental processes realized that all of the cells 
which later create tissues, organs and organisms arise from the differentiation of a single cell 
following fertilization (86). Later improvements to microscopy lead to further characterizations 
of what happens to the chromosomes during mitosis and along with the rediscovery of 
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rediscovery of Mendel’s Laws on Inheritance, tightly linked hereditary transmission of genetic 
material to the cell growth and division (86). Following Watson and Crick’s discovery of the 
DNA double-helix structure and further work describing the time at which DNA replication 
occurs during the cell cycle, the cell cycle was broadly divided into the four phases which we use 
to describe the cell cycle today, S-phase, when DNA replication occurs, M phase or mitosis, 
when cells and their genetic material are split and divided, and the gap phases (G1 before S-phase 
and G2 following S-phase, but before mitosis) (86–88). Cell fusion experiments performed by 
Rao and Johnson in 1970 determined that there is a one-way directionality in the cell cycle where 
cells proceed from G1 to S to G2 to M (89). During the late 1970’s through the 1980’s the 
essential molecular determinants of cell cycle progression were described (90–99). For their 
contributions in describing the molecular determinants of cell cycle control, Leland Hartwell, 
Timothy Hunt and Paul Nurse were awarded the 2001 Nobel Prize in Physiology or Medicine. 
Our understanding of the molecular determinants of cell cycle control continues to expand to this 
day as we determine how the integration of myriad factors and signaling pathways combine with 
the essential cell cycle control machinery to promote cell growth and division and how these 
processes, when aberrant, contribute to disease. 
Mechanisms of Control 
 The decision to commit to the cell cycle begins during G1 phase where the decision to 
proceed forward is regulated by sensing external growth factor signals from the environment and 
from internal signaling pathways which orchestrate the creation of various proteins and ready the 
necessary nutrients and macromolecules needed to ensure a successful cell division. Until the 
necessary factors are in place, the start of S-phase is restrained by a checkpoint known as the 
“restriction point” whereby cells either fully commit to completing the cell cycle, remain as they 
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are, or leave the cell cycle and enter a state of quiescence (G0) (100, 101). At a molecular level, it 
is conventionally believed that the liberation of the E2F family of transcription factors from the 
retinoblastoma protein (Rb) is essential for the transcription of a variety of genes necessary to 
both accelerate and maintain the liberation of E2F from Rb and trigger the processes needed for 
DNA synthesis to occur. In order for E2Fs to become liberated from Rb, Rb must be 
phosphorylated by cyclin D1 bound to cyclin-dependent kinases 4 and 6 (CDK4-6) (102). This 
phosphorylation event causes a conformational change in the Rb protein which frees E2F. This 
process is further maintained and accelerated by the increase in transcription of cyclin E1 (a 
transcriptional target of E2F), which when bound to CDK2 can promote the 
hyperphosphorylation of Rb. In order for this process of Rb phosphorylation to begin, cyclin D1 
levels must rise above the levels of the cyclin-dependent kinase inhibitors (CDIs) p16INK4A and 
p21WAF1 (103–107). Cyclin D1 levels typically peak during mid-G1, thus satisfying this 
requirement. Similarly, p27KIP1, functions to restrain cyclin E1-CDK2 activity (107, 108). 
Enzymes of the UPS also modulate the G1/S transition in a variety of ways. APC/CCDH1 restrains 
the G1/S transition by ubiquitinating a number of substrates involved in the G1/S transition (109). 
Loss of CDH1 accelerates the progression from G1/S. Similarly, SCFCyclinF promotes the 
transition from G1/S through targeting CDH1 for degradation, thus committing the cells to the S-
phase transition (110, 111). Additionally, SCFSKP2 promotes the G1/S transition through the 
degradation of the previously mention CDIs,  p27KIP1 and p21WAF1 (112–114). 
Once triggered, DNA synthesis occurs as multiple origins are fired which results in the 
unwinding of DNA and the recruitment and activation of replicative polymerases which generate 
a high-fidelity duplication of the cells genetic material (115). Any DNA damage caused during 
replication of the DNA will trigger an Intra-S-phase checkpoint which halts further progression 
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until the DNA damage is recognized, repaired and fixed. There are a variety of DNA damage 
sensing and repair mechanisms activated under a variety of conditions at this point and also in G2 
before the transition to mitosis occurs (116). 
Following S-phase, the cells enter G2 where similar to G1, many transcriptional, 
translational, and post-translational process connecting a variety of signaling networks come 
together to prepare the cell to divide into two daughter cells. The critical cyclin regulating the 
G2/M transition is cyclin B1. Cyclin B1 binds to its cognate kinase partner CDK1 in the 
cytoplasm (117). At this point, a number of molecular events must occur as the cell proceeds 
towards mitosis to fully activate the cyclin B1-CDK1 complex. First, CDK1 must be 
phosphorylated on T161 by CDK-activating kinase (CAK) and inhibitory phosphorylation on 
sites T14 and T15, orchestrated by the kinases WEE1 and Myt1 (118–121), must be removed by 
CDC25 (122–125). Second, active cyclin B1-CDK1 must be translocated from the cytoplasm to 
the nucleus in order to activate the processes necessary to complete mitosis (117). This largely 
occurs through phosphorylation events on cyclin B1 by kinases which include PLK1 (126, 127). 
These phosphorylation events block nuclear export factors, such as CRM1, from binding and 
exporting cyclin B1 and promotes the association with cyclin B1 with nuclear import factors to 
promote its import into the nucleus (117, 128–130). While in the nucleus, cyclin B1-CDK1 
activate further activate transcription factors such as B-MYB and FOXM1 (131–133) to facilitate 
the creation of many of the necessary proteins to begin mitosis and also induce changes in the 
microtubule network, actin microfilaments and the nuclear lamin (131, 134–136). 
 Mitosis, the final step in the cell cycle, can be separated into five distinct sub-phases 
(prophase, prometaphase, metaphase, anaphase and telophase) based on the physical state of 
chromosomes and spindle attachments. During prophase, chromosome condensation begins and 
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is largely orchestrated by the localization and activity of a protein called condensin (137). 
Cohesin is mostly removed from the arms of the chromosomes and the mitotic spindle beings to 
form as centrioles polarize within the cells and microtubules begin to polymerize from the 
centrosomes.  
Prometaphase is marked by nuclear envelope breakdown. This allows chromosomes to be 
accessed by the microtubules which connect to chromosomes at the kinetochores and ensure that 
sister chromatids have microtubule connections that will allow them to segregate to opposite 
poles. The activity of CDK1 and PLK1 are crucial for regulating centrosome and microtubule 
dynamics needed during this stage as well as in prophase (102, 138).  
During metaphase, the chromosomes align on the metaphase plate, the equator between 
spindle attachments. The spindle assembly checkpoint (SAC) is active during this period and 
ensures that chromosome microtubule and spindle attachments have been made and that the 
chromosomes are properly aligned. Mechanistically, unattached kinetochore promotes the 
creation of the mitotic checkpoint complex (MCC). This complex composed of the SAC proteins 
MAD2, BUBR1 and BUB3 bind the anaphase-promoting complex/cyclosome (APC/C) substrate 
recognition protein CDC20. APC/CCDC20 triggers the proteolytic degradation of cyclin B1 and 
securin, which are essential for the transition into anaphase (139, 140). The degradation of cyclin 
B1 inactivates CDK1, thus turning off the signal promoting the earlier stages of mitosis (141). 
The degradation of securin releases a protease called separase which degrades the cohesin ring 
holding sister chromatids together, thus allowing for their separation during anaphase (139, 142, 
143). When kinetochores are both correctly attached and under tension, a process regulated by 
the Aurora B kinase, the SAC signal is downregulated and the previously described proteolytic 
events are set in motion (139, 144). 
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During anaphase, the sister chromatids are pulled apart due to the degradation of cohesin, 
which previously kept sister chromatids attached, the shortening of kinetochore microtubules, 
which causes the chromatids to move towards the spindle poles and the movement of non-
kinetochore microtubules which further accelerate movement apart. Proteolytic destruction of 
many of the proteins essential for the G2/M transition continues during this time as the 
APC/CCDC20 gives way to APC/CCDH1 thus leading to the destruction of  additional mitotic 
proteins such as FOXM1, PLK1 and CDC20 itself (145). 
During telophase, the chromosomes have reached their respective poles and are fully 
separated. The nuclear membrane then reforms around the chromosomes and the chromosomes 
begin to expand. Mitosis ends with cytokinesis which sees the cytoplasm separated from one cell 
to two cells. 
 
Cell Cycle Transcription by FOXM1 
Background 
 The cell cycle transcription factor forkhead box protein M1 (FOXM1) will be a focus of 
the studies described in subsequent chapters. Here, I will give a general overview of FOXM1 
biology, how FOXM1 is regulated and the implications that this has on the cell cycle. Additional 
detail specifically describing the regulation of FOXM1 by the UPS and the role of FOXM1 in 
disease will be described as this information, as well as the open questions remaining, are critical 
to understanding how the work described in the subsequent chapters fits in to the broader context 
of the field. 
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Overview of FOXM1 Biology 
As previously mentioned, changes in transcriptional activity are central to establishing 
and ordering the distinct phases of the cell cycle as cells proceed from G1 to mitosis. One of 
these critical transcription factors is forkhead box protein M1 (FOXM1). FOXM1 was first 
cloned and characterized 25 years ago and is also known as MPP2, HFH-11, FKHL16, WIN and 
Trident as it was uniquely named following independent cloning of various groups in the mid 
1990’s (146–149). Further analysis of FOXM1 placed it within the forkhead box (FOX) family 
of evolutionarily conserved transcription factors (150). FOX family transcription factors are 
characterized by a common DNA binding motif with a preference for recognizing the 
“TAAACA” nucleic acid sequence, though this is not as predictive for FOXM1 promoter 
binding than it is with other FOX family proteins (151). Expression of FOXM1 oscillates 
throughout the cell cycle where levels are very low through most of G1, begin to rise at the G1/S 
transition, continue to rise through G2 and peak during the G2/M transition where levels 
precipitously drop due to rapid proteolytic degradation caused by the APC/CCDH1 (152, 153). As 
such, FOXM1 is only expressed in proliferating cells where it functions as a proliferation-
promoting transcription factor regulating the expression of a variety of genes associated with the 
G2/M transition and to a lesser extent, the G1/S transition (133, 154–156). Due to its central role 
in orchestrating the expression of a transcriptional network of genes needed for cell cycle 
progression, knockdown of FOXM1 is sufficient to slow proliferation whereas overexpression of 
FOXM1 is sufficient to drive proliferation (157–159). 
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Post-Translational Regulation of FOXM1 Through the Cell Cycle 
FOXM1 activity is tightly regulated throughout the cell cycle by a variety of post-
translational modifications including phosphorylation, ubiquitination, SUMOylation and 
acetylation (Figure 1.2). During G1, FOXM1 levels are low due to proteolytic degradation caused 
by the APC/CCDH1 (152, 153). As cells proceed closer to the G1/S transition, FOXM1 levels 
begin to rise, likely due to the inactivation of APC/CCDH1 at this point (110). Before becoming 
activated, the inhibitory N-terminal domain of FOXM1 must be phosphorylated, which releases 
it from association with its C-terminal transactivation domain (160). Though not entirely clear 
which kinases specifically phosphorylate the N-terminal domain to promote FOXM1 activation, 
it has been reported that FOXM1 is phosphorylated by cyclin D1-CDK4/6 and cyclin E1-CDK2 
during the G1/S transition (161, 162). This phosphorylation accomplishes a number of goals. 
First, it liberates FOXM1 from association with Rb (161, 163). Second, it allows for the 
recruitment of the p300/CBP transcriptional coactivator complex to FOXM1 which promotes 
FOXM1 acetylation (161, 164). This enhances the ability of FOXM1 to transcribe a number of 
genes essential for the G1/S transition and DNA damage repair (when further phosphorylated by 
CHK2) (162, 165, 166). Third, the phosphorylation of FOXM1 seems to promote its 
stabilization, though it remains unclear what factors may be modulating its stability during this 
time (162). FOXM1 dephosphorylation through binding to the phosphatase PP2A during this 
time restrains premature FOXM1 activation during this time (167). Interestingly, FOXM1 seems 
to promote the ubiquitination of proteins necessary to promote the G1/S transition though the 
enhancing the transcription of SKP2 and CKS1, two subunits of the SCF ubiquitin ligase 
complex (155). 
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 During S-phase, FOXM1 levels continue to rise and nuclear translocation is enhanced 
through phosphorylation from the Raf/MEK/MAPK signaling pathway (168). Additionally, 
FOXM1 is a downstream target of the Wnt-signaling pathway where Wnt signaling promotes 
FOXM1 association with β-catenin and subsequent nuclear translocation and activation of Wnt-
target gene expression (169). Also during late S-phase, FOXM1 is bound by the B-Myb-MuvB 
complex which targets FOXM1 to the promoters of mitotic genes containing the CHR sequence 
and may also increase the affinity of FOXM1 for its consensus “TAAACA” binding sequence 
which it has been demonstrated to have low affinity for (151, 170). 
 FOXM1 is at its peak in terms of both expression and activity throughout G2 through the 
prometaphase stage of mitosis. FOXM1 activity is heavily regulated by phosphorylation at this 
point. The C-terminal transactivation domain (TAD) of FOXM1 contains a multitude of 
phosphorylation sites and is phosphorylated by cyclin A1-CDK1, cyclin B1-CDK1, PLK1 and 
MELK (171–174). Hyperphosphorylation of FOXM1 by these kinases is essential for FOXM1 
transcriptional activation during this time and the targets of FOXM1 transcription are essential to 
executing the necessary processes to conduct mitosis and ensure that chromosomes segregation 
occurs without error (133, 155, 156, 171). The phosphatase CDC25B has also been shown to 
interact with FOXM1 at this time (161). FOXM1 is also SUMOylated during this phase of the 
cell cycle, though it is unclear if this modification activates or inhibits FOXM1 transcriptional 
activity (175–177). Following the transition from prometaphase to anaphase, FOXM1 and many 
of its transcriptional targets are rapidly ubiquitinated by APC/CCDH1 (152, 153). Recent work has 
demonstrated that the APC/CCDH1-mediated destruction of FOXM1 can be further enhanced 
through O-GlcNAcylation in a manner that depends on the activity of the deacetylase sirtuin 1 
(SIRT1), though the direct mechanism of action with respect to FOXM1 remains unclear (178). 
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Ubiquitin-dependent Regulation of FOXM1 
 Far less is known about the regulation of FOXM1 by ubiquitin when compared to what is 
known about phosphorylation-dependent regulation of FOXM1. As mentioned previously, 
ubiquitin-dependent degradation of FOXM1 orchestrated by interaction with the APC/CCDH1 
regulates the destruction of FOXM1 following the onset of anaphase and continues throughout 
G1 when APC/CCDH1 is active (152, 153). The N-terminus of FOXM1 contains the KEN box 
(amino acids K-E-N) and D-box (amino acids R-X-X-L) sequences which are recognized by 
APC/C and lead to K11 polyubiquitination on FOXM1 (179). Additionally, FOXM1 is 
ubiquitinated by two SCF E3 ubiquitin ligases, SCFFBXL2 and SCFFBXO31, the latter of which 
seems to primarily be active during G2/M to restrain FOXM1 levels (180, 181). SUMOylated 
FOXM1 has been demonstrated to be ubiquitinated by the E3 ubiquitin ligase RNF168 following 
epirubicin-induced DNA damage (182). FOXM1 is also ubiquitinated by SCFFBXW7 when 
FOXM1 is phosphorylated by the GSK3-Axin complex. This phosphorylation and ubiquitination 
event is inhibited by Wnt signaling (183).  
 At the time the studies described in Chapter 3 began, there were no DUBs linked to 
FOXM1 despite the fact that it is well established that FOXM1 levels are heavily regulated by 
ubiquitin. OTUB1 has been shown to promote the stability of FOXM1 by catalyzing the removal 
of K48-polyubiquitin chains (184, 185). USP5 has been shown to interact with FOXM1 
following Wnt signaling activation, thus promoting its stability through deubiquitination (183). 
 Intriguingly, FOXM1 seems to be targeted by naturally occurring thiopeptides which also 
happen to be general proteasome inhibitors (186). In two independent studies, thiostrepton and 
siomycin A were demonstrated to reduce the transcriptional activity of FOXM1 (187, 188). 
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Work remains to be done to determine the exact mechanism of binding of these thiopeptides to 
FOXM1 and to separate the effects on FOXM1 from the general proteotoxic stress induced from 
the general proteasomal inhibition that these molecules induce. 
As evidenced by what has been discovered about FOXM1 ubiquitination thus far, these 
processes are quite complex and involve the interplay of multiple signaling pathways. Much 
work remains to identify additional E3 ubiquitin ligases regulating FOXM1 abundance through 
the cell cycle and what signaling pathways are involved in modulating these effects. 
FOXM1 in Cancer 
 Due to its role as a proliferation-promoting transcription factor, the activity and 
overexpression of FOXM1 has been linked to a variety of cancers. FOXM1 is commonly 
identified as one of the most commonly upregulated genes in a variety of cancers. The FOXM1 
gene is located on 12p13 and copy number amplification at this site is common to a number of 
cancers (171). Additionally, FOXM1 expression levels typically correlate with poor prognosis 
and survival across most solid tumors (189). Importantly, in a multi-platform, high-throughput 
analysis of the genes most amplified in basal-like breast cancers and ovarian cancers carried out 
by The Cancer Genome Atlas Network, it was uncovered that FOXM1 is one of two master 
regulators which broadly promotes the amplification of most of the differentially expressed 
genes in those cancer subtypes (190). However, the correlation with FOXM1 and cancer is more 
than just a by-product of its general association with proliferative cells. Forced FOXM1 
overexpression or knockdown has been demonstrated to drive or retard cancer progression, 
respectively. Sustained expression of FOXM1 in murine models of colorectal, prostate, and lung 
cancer as well as hepatocellular carcinoma was enough to significantly accelerate the 
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development, proliferation and size of tumors formed and the knockdown or knockout of 
FOXM1 had the reciprocal effect in these same models (191–194).  
 In regard to cancer treatment, FOXM1 has also been demonstrated to modulate the 
response to chemotherapy. This is particularly concerning because chemotherapy remains the 
primary means of treatment for the management of many cancers which lack more targeted 
treatment options and many of these cancers are likely to overexpress FOXM1. FOXM1 
overexpression has been demonstrated to confer resistance to paclitaxel, a microtubule-
stabilizing drug which induces cell death through disrupting mitosis (195). FOXM1 knockdown 
increases sensitivity to paclitaxel. A FOXM1 transcriptional target, stathmin, a tubulin-
destabilizing protein, was suggested to be involved in the mechanism of paclitaxel sensitivity 
(195). FOXM1 has also been demonstrated to promote resistance to platinum-based 
chemotherapy. Platinum-based chemotherapies induce cell death by crosslinking with DNA to 
form adducts that result in DNA damage. FOXM1 expression was noted to be higher in MCF7 
breast cancer cell lines which had been made resistant to the platinum-based chemotherapy, 
cisplatin (196). Knockdown of FOXM1 in these cisplatin-resistant cells resensitized the cells to 
cisplatin. Mechanistically, FOXM1 seems to promote resistance to cisplatin through the 
activation of DNA damage repair mechanisms (196). Additionally, FOXM1 expression promotes 
resistance to the DNA intercalating chemotherapy epirubicin through a mechanism that hinges 
on FOXM1 regulation by ATM and p53 (197).   
Due to importance of FOXM1 in cancer initiation, progression and altering treatment 
outcomes, a great deal of attention has surrounded the promise of direct FOXM1 inhibition in 
treating cancer (158, 198). Unfortunately, this strategy is fraught with difficulties as transcription 
factors typically make poor drug targets. Most of the pharmacological inhibitors that have been 
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demonstrated to have an effect on FOXM1 bind to FOXM1 in a way that impairs the ability of 
FOXM1 to bind DNA (189, 199–202). These molecules tend to be large peptides which are 
typically difficult to deliver in a clinical setting. Additionally, many of these compounds are 
validated against the forkhead box DNA binding motif. Not only is this common to all FOX 
family transcription factors, FOXM1 has been shown to partner with other transcriptional 
coactivators to bind promoters that would not contain consensus FOXM1 DNA binding sites 
(169, 203, 204). Other strategies which have a more indirect effect on FOXM1 stability may be 
more pharmacologically viable. Small molecules which inhibit the transcription of FOXM1 
mRNA or the nuclear translocation of FOXM1 have recently been demonstrated (189, 205–207). 
In closing this introduction, I would like to emphasize that the path to realizing the 
promise of targeting FOXM1 as a therapeutic target lies in understanding the network of effects 
which regulate FOXM1. Not only will understanding the networks of proteins and signaling 
pathways that conspire together to activate FOXM1 throughout the cell cycle, inform our 
understanding of how FOXM1 is aberrantly activated or overexpressed in cancers where there is 
not a simple genetic explanation available to explain FOXM1 upregulation, but many of these 
proteins and signaling pathways may make excellent targets for small-molecule inhibitors. 
Notably, little is known about the ubiquitin-dependent regulation of FOXM1 relative to what is 
known about the phosphorylation-dependent regulation of FOXM1. In Chapter 2, I will describe 
the ubiquitin-dependent regulation of FOXM1 by CUL4-VPRBP. Not only does this E3 
ubiquitin ligase regulate the stability of FOXM1, but it also seems to activate FOXM1 
transcriptional activity, thus providing additional context to FOXM1 regulatory mechanisms that 
have never been previously described. In Chapter 3, I will describe the identification and 
characterization of FOXM1 by the DUB USP21. Not only does USP21 stabilize FOXM1 
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through the removal of polyubiquitin chains, but the amplification of the genomic region 
containing the USP21 gene may partly explain why FOXM1 is elevated in cancers with a 1q21-
23 copy number amplification as is commonly observed in basal-like breast cancers. Moreover, 
it will be demonstrated that USP21 knockdown can slow proliferation in a FOXM1-dependent 
manner and that the targeting of USP21 can sensitize breast cancer cells to paclitaxel and may 
prove a viable therapeutic strategy to use in conjunction with chemotherapy to target cancers 






















Figure 1.1 Overview of the ubiquitin-proteasome system. A graphical depiction of substrate ubiquitination by a 
cullin-RING ubiquitin ligase. The cascade begins when ubiquitin (U) is conjugated onto an E1 ubiquitin-activating 
enzyme (E1) in an ATP-dependent reaction. This ubiquitin molecule is then transferred onto an E2 ubiquitin-
conjugating enzyme (E2). This enzyme is able to be incorporated into a culling-RING ligase complex (RING, CUL, 
ROC1/2) which also contains an E3 ubiquitin ligase substrate adaptor (E3). When activated by NEDD8 (N8), 
substrates are able to be ubiquitinated as ubiquitin moves from the E2 to the substrate attached to the E3. These 
proteins can interact with ubiquitin-binding proteins (UBPs), be degraded by the 26S proteasome (26S) or interact 
with deubiquitinating enzymes which remove conjugated ubiquitin. Cullin-RING ligases can also be inactivated by 
the COP9 signalsome (CSN), which deNEDDylates the complex. CAND1 can also inactivate the cullin scaffold by 














Figure 1.2 FOXM1 post-translational modification landscape. A graphical overview of the known proteins and 
sites which post-translationally modify FOXM1. E3 ubiquitin ligases and deubiquitinating enzymes in dark green 
were added as a result of the work described in the subsequent chapters. Matching colors between kinases and 
phosphorylation sites denotes sites that are uniquely modified by that kinase. Black color for phosphorylation sites 




CHAPTER 2: VPRBP/DCAF1 REGULATES THE DEGRADATION AND 




 Changes in gene expression combined with targeted protein degradation dynamically 
shape the protein landscape. Gene expression is coordinated by transcription factors that specify 
genes for activation and cofactors that modulate transcription factor activity or alter the local 
chromatin environment. Post-translational modifications (PTMs) play a crucial role in 
transcriptional dynamics. Phosphorylation, acetylation, methylation and ubiquitylation of histone 
proteins is well-studied, and contributes significantly to gene expression dynamics (208). 
Similarly, post-translational modification of transcription factors plays an important role in 
regulating genome output. 
 FOXM1 is an oncogenic, cell cycle regulated transcription factor that was discovered as 
both a marker and key mediator of cell proliferation (147, 157, 209). Subsequent work clarified 
the importance of FOXM1 in proliferation through its role in cell cycle progression (210). 
FOXM1 controls the mitotic transcriptional program and its depletion significantly impairs 
normal mitotic entry and progression (156, 211–213). In addition, FOXM1 and its transcriptional 
network have been associated with numerous cancers (158, 210). Notably, FOXM1 is the key 
regulator of a proliferative gene expression signature found in high-grade serous ovarian cancer 
                                               
1 This chapter previously appeared as an article in Molecular and Cellular Biology. The original citation is as 
follows: X. Wang, A. Arceci, K. Bird, C. A. Mills, R. Choudhury, J. L. Kernan, C. Zhou, V. Bae-Jump, A. Bowers, 
M. J. Emanuele, VprBP/DCAF1 regulates the degradation and nonproteolytic activation of the cell cycle 
transcription factor FoxM1. MCB. 37, 13, e00609-16 (2017). 
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(HGSOC), basal-like breast cancers and uterine serous carcinomas (190, 214, 215). In HGSOC 
the FOXM1 signature is found in ~90% of patient tumors (214).  
 FOXM1 activity peaks in G2/M phase, consistent with its role in dictating mitotic gene 
expression, and several kinases have been implicated in its activation (155, 170, 204, 211, 216, 
217). FOXM1 is repressed by an intra-molecular interaction with its amino-terminal domain and 
this inhibition is relieved by cyclin-dependent kinase (CDK) phosphorylation (160). In addition, 
the cell cycle kinases MELK and PLK1 can activate FOXM1 (161, 172–174, 177).  
 In addition to phosphorylation, post-translational addition of ubiquitin is utilized to 
control gene expression. The oncogenic transcription factor c-Myc highlights the complex role of 
ubiquitin in transcriptional regulation (218). Myc is targeted for proteolysis by several E3 
ubiquitin ligases, including a SCF-type Cullin Ring Ligase (CRL) and the substrate receptor 
SKP2 (SCFSKP2) (219, 220). Whereas protein ubiquitylation and degradation are most often 
considered inactivating events, unexpectedly, SKP2 activates Myc dependent transcription (219, 
220). Ubiquitylation dependent activation of Myc is further borne out by studies using a lysine-
less version that cannot be ubiquitylated and is deficient in activating transcription (221). The 
role of ubiquitylation in transcriptional activation builds on pioneering studies on the VP16 
transcription activation domain whose activation in yeast requires an SCF ligase together with its 
substrate receptor Met30 (222). Furthermore, the ability of the ubiquitin machinery to activate 
transcription is corroborated by regulation of the human estrogen receptor (ERa) and its 
coactivator, SRC-3/AIB1, whose degradation is coupled to activation (222–225). Together, these 
studies highlight the complex role ubiquitin plays in transcriptional control. 
 The role of ubiquitin ligases in activating FOXM1 has not been studied. We recovered 
FOXM1 in a global screen for substrates of the modular CRLs, which represent the largest E3 
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ligase family in humans (6). CRL assembly is based on a common molecular scaffold and relies 
on a cullin backbone that simultaneously engages substrates and E2 ubiquitin-conjugating 
enzymes. Cullin4-based ligases (CRL4) use either of two highly related cullin proteins, CUL4A 
or CUL4B, that bind to the triple-β-propeller protein DDB1 and simultaneously recruit specific 
proteins to the enzyme complex for ubiquitylation (Figure 2.1A) (226). Human CUL4A and 
CUL4B are highly similar (75% amino acid similarity), however CUL4B has an amino-terminal 
extension and localizes exclusively to the nucleus, whereas CUL4A is both nuclear and 
cytoplasmic (227). Importantly, CRL4 function has been linked to chromatin regulation, cell 
cycle, viral infection, and the DNA damage response (226). 
 More than 50 CRL4 substrate receptors, termed DCAFs or DWD proteins (DDB1 and 
CUL4 Associated Factors; DDB1 binding WD40 proteins), have been identified (26, 228, 229). 
VPRBP/DCAF1 is a nucleus-localized CRL4 substrate receptor named for its ability to bind the 
HIV accessory protein Vpr (and Vpx) following viral infection (36). Ectopic Vpr expression in 
human cells triggers a G2 arrest that is dependent on CRL4VPRBP (47). Significantly, VPRBP  
associates with chromatin only during G2/M phase of the cell cycle (230). Knockout of VPRBP 
in mice causes embryonic death prior to embryonic day 7.5 (E7.5), and conditional inactivation 
of VPRBP in mouse cells or depletion using RNA interference (RNAi) in human cells, produces 
cell cycle defects (230). Despite its importance in cell cycle control and development, 
CRL4VPRBP has few known substrates and it remains unclear how it contributes to cell cycle 
progression. Endogenous CRL4VPRBP substrates include the methylcytosine dioxygenase Tet2 
(231) and the replication regulator Mcm10 (232). Other proteins are targeted for ubiquitylation 
only in response to HIV infection and include the phosphohydrolase SAMHD1 (40). VPRBP has 
been linked to the NF2 tumor suppressor and YAP dependent transcription, suggesting a role in 
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transcriptional regulation and cancer (233). Here, we describe a role for VPRBP in controlling 
both the degradation and activation of FOXM1.   
Results 
FOXM1 Stability is Regulated by CRL4VPRBP 
 Using a fluorescence-based genetic reporter system termed global protein stability 
Profiling (GPS) we previously searched for substrates of the CUL4-based Cullin-RING ligase 
(CRL4) (6). The GPS expression system relies on a viral vector that expresses a bicistronic 
mRNA encoding both DsRed and an enhanced green fluorescent protein-open reading frame 
(EGFP-ORF) fusion protein. Using this system, we infer relative changes in the stability of 
EGFP-ORF fusions by examining the ratio between EGFP and DsRed fluorescence using flow 
cytometry. DsRed normalizes for expression of the reporter cassette on a single cell basis. Using 
this system, we screened a pooled library of 293T cell expressing more than 13,000 individual 
EGFP-ORF fusion proteins (one ORF per cell). A schematic overview of the GPS screening 
system is described in detail elsewhere (6, 234). 
 To identify proteins whose stability are controlled by CRL4, we turned off the ligase by 
introducing a dominant-negative construct targeting CUL4 and compared this condition to a 
negative-control vector (6). GPS-library cells from these two conditions were sorted into bins 
based on their EGFP/DsRed ratio using fluorescence activated cell sorting (FACS). Genomic 
DNA (gDNA) was isolated from sorted cells in each bin, and ORFs were amplified from gDNA 
using PCR primers designed against the viral backbone. Amplified ORF DNA was labeled and 
hybridized to custom-designed DNA microarrays containing multiple independent probes per 
gene. Quantifying the distribution of probe signals across bins allows us to infer changes in the 
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stability for EGFP-ORFs (6). For example, a shift in the probe distribution to higher-numbered 
bins suggests that cells expressing a particular EGFP-ORF showed an increase in their 
EGFP/DsRed ratio, indicative of an increase in the stability of the EGFP-ORF fusion protein. 
 Three of the four probes corresponding to FOXM1 showed a shifted distribution after 
dominant-negative CUL4 treatment, suggesting that EGFP-FOXM1 was stabilized by CRL4 
inactivation (Figure 2.1B). These three probes showed a highly consistent distribution across bins 
suggesting that they accurately report the distribution of EGFP-FOXM1 expressing cells and that 
FOXM1 stability is regulated by CRL4.  
 To validate endogenous FOXM1 as a CRL substrate we treated cells with MLN4924, a 
pharmacological small-molecule inhibitor that impairs CRL activation by interfering with the 
neddylation cascade (235). FOXM1 abundance was increased after a 4 h MLN4924 treatment in 
both 293T and U2OS cells (Figure 2.1C). The slower migrating, neddylated form of CUL4 was 
undetectable after MLN4924 treatment, showing that neddylation was impaired. We next 
determined if FOXM1 is regulated by CUL4. We treated cells with small interfering RNA (siRNA) 
targeting either CUL4A, CUL4B, DDB1 or with control oligonucleotides targeting firefly 
luciferase (FF). Seventy-two hours after transfection cells were harvested for immunoblot. 
Depletion of DDB1 and CUL4B lead to a reproducible increase in the abundance of endogenous 
FOXM1, whereas depletion of CUL4A had a weaker and less consistent effect (Figure 2.1D). 
Consistently, depletion of DDB1 and CUL4B increases the abundance of Myc-FOXM1, which is 
stably expressed form a heterologous promoter, and again, CUL4A had no effect (Figure 2.1E; the 
underline corresponds to the antigen used for blotting (e.g. Myc-FOXM1)). Taken together, these 
data suggest FOXM1 stability is regulated by CRL4. 
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The two best-studied CRL4 substrate receptors implicated in cell cycle control are CDT2 
and VPRBP. CDT2 engages substrates through a degron embedded within a PCNA-interacting 
peptide motif (PIP-box) (236). However, FOXM1 lacks a PIP-box. We therefore depleted VPRBP 
using siRNA and measured FOXM1 abundance by immunoblot. Depletion of VPRBP increased 
endogenous FOXM1, as well as the known substrate MCM10, in both HeLa and U2OS cells 
(Figure 2.1F).  
 FOXM1 is degraded in G1 phase by the anaphase-promoting complex/cyclosome-CDH1 
(APC/CCDH1) ubiquitin ligase (153, 237). To determine if VPRBP regulates FOXM1 at other times 
during the cell cycle and to rule out the possibility that differences in FOXM1 abundance where 
due to changes in cell cycle progression, we treated U2OS cells with siRNA targeting VPRBP and 
then synchronized cells using thymidine in accordance with a previously established protocol 
(238). Cells were harvested 0, 2, 4 and 6 h after release and analyzed by immunoblot. FOXM1 
was consistently increased in the VPRBP-depleted cells (Figure 2.2B), suggesting that VPRBP 
regulates FOXM1 degradation and that the increase in FOXM1 abundance is independent of gross 
cell cycle changes. Two independent siRNA oligonucleotides targeting VPRBP produced a similar 
increase in FOXM1 levels in S-phase synchronized cells (Figure 2.2C). Similarly, we 
synchronized HCT116 cells in early S-phase, late S-phase/G2 and G2/M using thymidine, 
thymidine block and release, and nocodazole, respectively. FOXM1 was increased in 
synchronized, VPRBP-depleted cells, indicating that VPRBP controls FOXM1 independent of its 
effect on the cell cycle (Figure 2.2D). 
 Next, we measured FOXM1 stability/half-life in control and VPRBP-depleted cells that 
were synchronized in S-phase, 2 h after thymidine release. VPRBP depletion increased FOXM1 
stability after treatment with the protein synthesis inhibitor cycloheximide (CHX) (Figure 2.1G). 
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This is a reproducible result observed across several experiments. The increase in FOXM1 is 
evident in otherwise untreated cells after the addition of CHX (Figure 2.2E). While the mechanism 
underlying this phenomenon remains unclear, it has long been appreciated that some proteins can 
increase following treatment with CHX (239). 
FOXM1 Interaction and Ubiquitylation by VPRBP 
 We determined if VPRBP binds to FOXM1 in 293T cells transiently transfected with 
Myc-FOXM1 and hemagglutinin-tagged VPRBP (HA-VPRBP) to examine the possibility that 
FOXM1 is a direct CRL4VPRBP substrate. Cells were treated with the proteasome inhibitor 
MG132 for 4 h prior to lysis and co-immunoprecipitation (co-IP) to promote the interaction 
between E3 ligase and substrate (240, 241). Following anti-HA-VPRBP IP, we detected an 
interaction with FOXM1, and this interaction was enhanced by treatment with MG132 (Figure 
2.3A and Figure 2.4A). The interaction was also detectable when Myc-FOXM1 was 
immunoprecipitated (Figure 2.4C). In addition, we immunoprecipitated endogenous FOXM1 
from 293T cell lysates and detected endogenous VPRBP (Figure 2.3B). Finally, we determined if 
FOXM1 and VPRBP can directly interact. We immobilized bacterially purified hexahistidine-
tagged FOXM1 (FOXM1-6HIS) on nickel-agarose beads and mixed them with purified, 
[35S]methionine-labeled VPRBP produced in vitro using purified transcription and translation 
machinery. VPRBP bound to beads that had immobilized FOXM1-6HIS but was observed only 
in the flow through of control beads, strongly suggestive of a direct interaction (Figure 2.3C). 
To determine if VPRBP can regulate FOXM1 ubiquitylation we ectopically expressed 
6HIS-ubiquitin in 293T cells with and without HA-VPRBP. Cells were treated with MG132 prior 
to lysis in strong denaturing buffer (6M Guanidine-HCl) and 6HIS-ubiquitin conjugates were 
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isolated on nickel-agarose. VPRBP expression enhanced the ubiquitylation of endogenous 
FOXM1, measured by immunoblotting for FOXM1 (Figure 2.3D). Likewise, VPRBP significantly 
increased the ubiquitylation of ectopically expressed Myc-FOXM1 (Figure 2.3E). Therefore, 
VPRBP regulates the abundance, stability and ubiquitylation of FOXM1. 
 To identify the domain in FOXM1 that interacts with VPRBP we synthesized a series of 
constructs encoding 160 amino acid (aa) fragments of the FOXM1 protein spanning the length of 
its largest known open reading frame. We tested their ability to interact by expressing full-length 
HA-VPRBP and Myc-FOXM1 fragments in 293T cells and analyzing precipitates after anti-HA 
IP. A fragment of FOXM1 spanning amino acids 321-480 (FOXM1321-480) interacted most 
strongly with VPRBP (Figure 2.4B). The same Myc-FOXM1321-480 fragment bound to VPRBP 
when Myc was precipitated (Figure 2.4C). We conclude that the interaction between VPRBP and 
FOXM1 is dependent on the region of FOXM1 spanning amino acids 321-480. 
 To identify the degron sequence motif in FOXM1 we examined molecular and structural 
data of a known VPRBP substrate. SAMHD1 is targeted by CRL4VPRBP after HIV infection, and 
a ternary complex between VPRBP, SAMHD1 and the viral accessory protein Vpx has been 
crystalized (Figure 2.3F) (42). Importantly, the amino acids in SAMHD1 that mediate binding to 
VPRBP and degradation have been mapped (41, 42). A segment between amino acids 615 and 
625 in SAMHD1 contributes significantly to VPRBP binding and several residues in this region 
are critical for its degradation. We looked for matching sequences in FOXM1 between residues 
321 and 480 and identified a region of similarity between residues 414 and 422 (Figure 2.3F). 
We synthesized three mutant versions of the same 321-480 region, making amino acid 
substitutions that correspond to residues which we predicted would affect recognition by 
VPRBP. These substitutions in FOXM1 included changed of RV to AA (aa 416 and 417), RI to 
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AA (aa 418 and 419), and K to A (aa 422). We tested the ability of each version of the fragment 
to bind HA-VPRBP by co-IP following treatment with proteasome inhibitors to normalize 
protein levels across IPs. We found that alanine substitutions at residues 418 and 419 (RI to AA) 
and 422 (K to A) impaired binding to VPRBP (Figure 2.3G). Notably, K622 in SAMHD1, 
corresponding to K422 in FOXM1, directly contacts VPRBP in the crystal structure and is 
required for SAMHD1 degradation (42). 
 We next tested the stability of these fragments by CHX chase. Significantly, fragments 
that showed reduced binding also had higher basal expression (note these experiments were not 
done in proteasome inhibitors) and increased stability relative to the wild type (WT) fragment 
when expressed in 293T cells (Figure 2.3H). We observed a similar increase in the stability of 
full-length FOXM1 when amino acids in the putative degron motif were changed (RVRIAPK to 
AAAAAPA; the half-life increased from 1.0 to 1.5 h). Minor changes, specifically K422A, 
similarly extended the half-life (Figure 2.2F and 2.2G). These data are suggestive that this motif 
sequence, R-I/V-X-X-(X)-K, represents a putative VPRBP degron. Similar sequences were 
found in established substrates TET2 and MCM10 (Figure 2.3F) (231, 232). 
VPRBP is a FOXM1 Activator 
To address the contribution of VPRBP to FOXM1 activity we utilized a well-characterized 
FOXM1 luciferase reporter construct (6xDB) (161). We measured reporter activity following 
transient expression of FOXM1 and VPRBP in 293T cells. Expression of FOXM1 increased 
reporter activity as expected (Figure 2.5A). Remarkably, we also observed a strong, dose-
dependent increase in reporter activity in response to VPRBP when co-expressed with FOXM1 
(Figure 2.5A). We compared the ability of VPRBP to activate FOXM1 activity to the known 
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coactivator MELK (174). VPRBP activated the reporter to a greater extent than MELK when 
transfected in equal amounts (Figure 2.5B). Furthermore, VPRBP activates the 6xDB reporter in 
the absence of ectopically expressed FOXM1 (Figure 2.5B). We also measured the effect of 
VPRBP on an unrelated luciferase reporter controlled by the oxidative stress response transcription 
factor Nrf2. FOXM1 and VPRBP expression did not affect the Nrf2 luciferase reporter, whereas 
strong activation was achieved by Nrf2 expression (Figure 2.6A). 
We next expressed the 6xDB reporter with increasing amounts of VPRBP and analyzed 
luciferase activity, cell cycle dynamics and protein abundance all in the same experiment (Figure 
2.5C). VPRBP activated reporter activity at both 24 and 48 h post-transfection in a dose-dependent 
manner (Figure 2.5C.1). Importantly, the abundance of FOXM1 remained unchanged at both time 
points and concentrations of VPRBP (Figure 2.5C.2). This demonstrates that the change in reporter 
activity is not due to changes in the overall level of FOXM1. It also suggests that VPRBP does not 
activate FOXM1 by triggering its degradation, as is the case for Myc activation by SKP2 (219, 
220). We examined the cell cycle using propidium iodide staining and analysis by flow cytometry 
and found no significant changes at either time point relative to controls (Figure 2.5C.3). We 
therefore conclude that VPRBP activates FOXM1, and that activation is independent of FOXM1 
abundance, and is not due to gross changes in cell cycle dynamics. 
To directly interrogate the consequence of VPRBP depletion on FOXM1 activity, we 
measured the transcript levels of FOXM1 target genes in synchronized U2OS cells (to alleviate 
cell cycle effects) that were depleted of VPRBP. First, U2OS cells were synchronized in G2/M 
following an 8 h release from thymidine block. The mRNA from control and VPRBP-depleted 
cells was isolated and FOXM1 target gene expression was measured using quantitative reverse 
transcription PCR (RT-qPCR). The expression of several FOXM1 target genes was reduced in 
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VPRBP depleted cells, including CDC25B, CCNB1, PLK1 and CENPF (Figure 2.7A). The 
expression of VPRBP was reduced by siRNA treatment as expected; however, the level of FOXM1 
mRNA was unchanged. We performed a similar experiment by treating cells with siRNA targeting 
FF, FOXM1, and VPRBP, and then blocking cells in mitosis with nocodazole. Mitotic cells were 
specifically isolated by shake-off and we found that the expression of CDC25B, PLK1 and CCNB1 
were reduced to a similar extent in both FOXM1 and VPRBP-depleted cells relative to controls 
(Figure 2.6B). We therefore conclude that VPRBP activates the transcription of FOXM1 target 
genes during G2/M phase of the cell cycle.  
FOXM1 has been implicated in mitotic entry and progression (211, 212). We next 
examined the role of VPRBP in mitotic entry since its depletion reduces the expression of several 
FOXM1 target genes. U2OS cells were treated with either control or VPRBP siRNAs and after 72 
h were fixed and processed for phospho-histone H3 (P-H3) immunostaining to mark mitotic cells. 
Imaging was performed and the percent of P-H3 positive cells was determined. 8% of cells were 
in mitosis in control depleted populations (Figure 2.7B). Depletion with two independent VPRBP 
siRNAs significantly reduced the percentage of P-H3 positive mitotic cells, to 2.8% and 0.5% 
(Figure 2.7B). Thus, VPRBP depletion blocks the accumulation of mitotic cell cycle genes and 
prevents M-phase entry, consistent with a role for VPRBP in activating FOXM1.  
We determined if VPRBP localizes to the promoters of FOXM1 target genes since it binds 
FOXM1 and regulates FOXM1 target gene expression. U2OS cells were synchronized in G2/M 
phase and processed for chromatin immunoprecipitation (ChIP). Immunoprecipitation was 
performed in parallel with antibodies to control IgG, FOXM1 and VPRBP. We detected an 
enrichment of VPRBP and FOXM1 at the promoters of previously characterized FOXM1 
promoters, including PTMS, BRCA2 and FZR1 (217). In addition, VPRBP localized to a lesser 
 36 
extent to the FOXM1 targets CENPF and CDK1 (Figure 2.8A). Thus, FOXM1 and VPRBP co-
localize to FOXM1 target promoters. 
 Myc and ERα are activated by ubiquitylation via their respective ligases (219, 220, 242). 
We sought to gain similar mechanistic insight into the regulation of FOXM1 by VPRBP. We 
determined if two independent versions of VPRBP that cannot bind DDB1 (N909 and RARA) are 
able to activate FOXM1 reporter activity (231). The 6xDB reporter activity was increased using 
an amino-terminal fragment of VPRBP (N909) which cannot bind to the DDB1/CUL4 complex 
(Figure 2.8B). Similar results were obtained with a mutant version of VPRBP (RARA) that is also 
impaired in DDB1/CUL4 binding (Figure 2.8B) (231). Further, the response of 6xDB to 
VPRBPWT, VPRBPN909 and VPRBPRARA is dose dependent (Figure 2.6C). We conclude that 
VPRBP activation of FOXM1 is independent of the CRL4 complex. These data also suggest that 
FOXM1 activation by VPRBP is not due to a change in the abundance or stability of a secondary, 
unknown CRL4VPRBP substrate. 
 We next asked if VPRBP is still bound to CUL4B and DDB1 at a time in the cell cycle 
when FOXM1 is active. We introduced HA-VPRBP into 293T cells that were then treated with 
either nocodazole or dimethyl sulfoxide (DMSO). Cells were lysed and HA immunoprecipitates 
were analyzed by immunoblot. We found that the association of HA-VPRBP with endogenous 
CUL4B, and to a lesser extent DDB1, was reduced in mitotic cells (Figure 2.8C, lane 6 vs 8). 
However, there was no change in the interaction between VPRBP and FOXM1 in mitosis (Figure 
2.8C and 2.8D). Thus, VPRBP association with the CRL4 complex is cell cycle regulated, and its 
dissociation coincides with the time at which FOXM1 is activated. 
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VPRBP Protein is Upregulated in High-Grade Serous Ovarian Tumors 
 The FOXM1 gene expression signature is upregulated in ~90% of high-grade serous 
ovarian cancers (HGSOC) (214). However, FOXM1 mRNA is only overexpressed in ~12% of 
tumors. To analyze the expression of VPRBP in HGSOC tumors we obtained surgically resected 
ovaries from HGSOC patients that had been histologically confirmed as serous ovarian cancer. 
As controls we examined ovaries from women who underwent oophorectomy for reasons other 
than gynecological malignancy. FOXM1 levels were not elevated in HGSOC tumors relative to 
controls. Remarkably, VPRBP protein was upregulated in seven out of nine HGSOC tumors 
tested relative to control ovaries where VPRBP levels were low or undetectable (Figure 2.9A). 
Further, the well-established FOXM1 target cyclin B was expressed in six of the seven tumors 
where VPRBP was increased. VPRBP mRNA is not overexpressed in HGSOC based on genomic 
analysis, suggesting that post-transcriptional mechanisms account for its overexpression (214). 
 
Discussion 
 Ubiquitylation has long been implicated as a key regulator of transcription and chromatin 
regulation in human cells. Ubiquitin was identified due to its conjugation to the core histone 
H2A, and only later was identified by Hershko and colleagues as part of intracellular protein 
degradation system (243). The yeast α-2 transcriptional repressor was one of the first identified 
in vivo targets of ubiquitin dependent protein degradation (244). Ubiquitin has been most well 
described for its role in inactivating target proteins through proteolysis. However, the emergence 
of complex ubiquitin chains of varying topologies and the identification of their roles in various 
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aspects of cellular physiology, beside protein degradation, illustrates the complex and sometimes 
paradoxical role the ubiquitin machinery can play in signal transduction. 
 These multiple functions are evident in the role of ubiquitin signaling in transcriptional 
regulation, where transcription factors and coactivators can be activated by the ubiquitin 
machinery. For example, the transcriptional activation domain (TAD) of VP16 is activated in 
yeast by the SCF substrate receptor F-box protein, MET30 (222). Moreover, fusion of ubiquitin 
directly to VP16 restores its activity in the absence of MET30 without effecting VP16-TAD 
stability, providing an example of ubiquitin-dependent, degradation-independent transcriptional 
activation (222). There are also well-established examples of ubiquitin- and proteasome-
dependent transcriptional activation in human cells. First is the Myc transcription factor. Myc 
degradation is controlled by the SCFSKP2 E3 ubiquitin ligase and SKP2 also promotes Myc 
transcriptional activation (219, 220). Consistently, a lysine-less version of Myc, which cannot be 
ubiquitylated and degraded with normal kinetics, still binds to the coactivator Max and localizes 
to target gene promoters but is unable to fully activate gene expression (221). Similarly, ERa is 
ubiquitylated and degraded in response to ligand (estrogen) and this is required for its full 
activation (223). 
Here we show a FOXM1 activation mechanism that is both ubiquitin- and degradation- 
independent yet involves a component of the ubiquitin system that can also regulate its destruction. 
We found that FOXM1 is a substrate of the CRL4VPRBP E3 ubiquitin ligase. Analogous to Myc 
activation by SKP2, we discovered that VPRBP potently activates FOXM1. However, the FOXM1 
reporter was activated by two independent versions of VPRBP that are impaired in binding to 
CRL4. Moreover, we demonstrate biochemically that VPRBP is dissociated from the CRL4 
complex at the time during the cell cycle when FOXM1 activity peaks. Together, these data 
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suggest that FOXM1 activation by VPRBP is ubiquitin- and degradation- independent. The ability 
of VPRBP to activate FOXM1 independently of CRL4 binding provides a clear demonstration of 
E3 ligase substrate receptor repurposing. Moreover, it suggests the possibility that the activity of 
other CRL substrate receptors can be context dependent and dynamically altered by controlling 
their association with ubiquitin machinery. 
 We hypothesize that VPRBP acts as a rheostat to control FOXM1 degradation and 
activation (Figure 2.9B). FOXM1 abundance is tightly controlled throughout the cell cycle by 
ubiquitination. By tempering FOXM1 accumulation, VPRBP could impair its activation. Late in 
the cell cycle, before mitosis, FOXM1 activity increases, contributing significantly to the 
expression of genes involved in mitotic entry and progression (156). At this time, the partial 
dissociation of VPRBP from DDB1 and CUL4 (Figure 2.8) would enhance its ability to activate 
FOXM1 (216). Consistent with this prediction, VPRBP partially dissociates from CRL4 in mitosis 
and a mutant version of VPRBP that is impaired for DDB1 binding can still activate FOXM1. 
Importantly, since VPRBP depletion increases FOXM1 protein levels in mitotic cells, it is unlikely 
that VPRBP acts through a switch-like mechanism, whereby it is either targeting FOXM1 for 
degradation of promoting its activation. In a rheostat model, VPRBP could tune the output of 
FOXM1 by controlling both its activation and its degradation with the relative role of each in a 
given cell determined by the extent of CRL4VPRBP disassembly. It is interesting that VPRBP is 
unique among CRL4 substrate receptors in that it is likely stoichiometrically bound to CRL4 (230, 
245). In addition, VPRBP association with chromatin is tightly cell cycle regulated and occurs 
only at the time when FOXM1 is activated (G2/M). 
 The mechanism by which VPRBP dissociates from CRL4 remains unknown. We predict 
that post-translational modification of VPRBP could alter its chromatin association and/or binding 
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to DDB1/CUL4. Alternatively, modification of DDB1 or CUL4 could regulate their association 
with VPRBP. Modifications that affect FOXM1-VPRBP binding cannot be ruled out, although 
they did not change in mitosis in our experiments. It is interesting that CHK2 phosphorylates 
FOXM1 in the same region as the one that we mapped as being important for VPRBP binding 
(165) and CHK2 has been linked to mitotic progression (246). Dissecting the signaling pathways 
that control the relationship and interactions between VPRBP, CRL4 and FOXM1 is an important 
area of future study. 
 FOXM1 is activated in variety of human malignancies. Specifically, its transcriptional 
signature is upregulated in HGSOC, serous uterine cancer and basal-like breast cancer. (190, 214, 
215). However, it is mechanistically unclear how FOXM1 is activated in each of these disease 
subtypes. Defects in ubiquitin signaling have been linked to changes in transcription factor stability 
in malignancies. This is illustrated by the regulation of p53 by MDM2, as well as mutations 
FBXW7 that effect Myc. Unlike these two, prominent examples, VPRBP is neither significantly 
mutated nor transcriptionally altered in cancers in which the FOXM1 signature is upregulated. 
However, we show that VPRBP is overexpressed at the protein level in HGSOC patient tumors. 
This suggests that VPRBP might, in part, contribute to the FOXM1 expression signature observed 
in these cancers. It is important to note that cyclin B gene and other G2/M genes can be controlled 
by multiple factors and FOXM1 itself is controlled by myriad mechanisms. Since VPRBP is not 
overexpressed at the mRNA level based on transcriptomic analysis, it is presumably due to 
regulation of either its translation or its degradation. Cross-talk between cell cycle E3 ligases is an 




Materials and Methods 
Immunoblot Analysis 
Cell extracts were prepared by lysis in ice-cold NETN buffer (20 mM Tris pH 8.0, 100 
mM NaCl, 0.5 mM EDTA, 0.5% NP40, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride 
(AEBSF), 10 μg/ml leupeptin, 2 μg/ml aprotonin, 2 μg/ml pepstatin A). Cell were lysed on ice 
for 15 minutes and then centrifuged at 14,000 rpm for 15 minutes at 4°C. Supernatant was 
collected and protein concentrations were determined by Bradford assay.  
Tumor specimens were sampled from patients undergoing surgery for HGSOC at the 
University of North Carolina at Chapel Hill. The protocol was reviewed, and exemption granted 
by the Institutional Review Board at the University. To extract protein from tissues, normal 
ovarian tissues and ovarian tumors were homogenized in ice-cold tissue homogenizing buffer 
(10 mM HEPES (pH 7.4), 50 mM β-glycerophosphate, 1% Triton X-100, 10% glycerol, 2 mM 
EDTA, 2 mM EGTA, 1 mM dithiothreitol (DTT), 10 mM NaF, 1 mM Na3VO4, 10 μg/ml 
leupeptin, 2 μg/ml aprotonin, 2 μg/ml pepstatin A, and 1 mM AEBSF) using TissueLyser II 
(Qiagen). The homogenates were placed on ice for 15 minutes and then centrifuged at 14,000 
rpm for 15 minutes at 4°C. Supernatant was collected, and protein concentrations were 
determined by Bradford assay. 
 For immunoblotting, samples were heated for 5 minutes at 95°C before electrophoresis. 
Samples were analyzed by SDS-PAGE using either homemade or Bio-Rad TGX gels which were 
subsequently transferred onto nitrocellulose membranes (Bio-Rad). Membranes were blocked with 
5% bovine serum albumin (BSA). Antibodies were incubated overnight, and signals were detected 
using Pierce ECL (Thermo Scientific). The primary antibodies used for immunoblotting analysis, 
their source and the concentrations used are described in detail in Table 2.1. Secondary antibodies 
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conjugated to horseradish peroxidase (HRP) were purchased from Jackson ImmunoResearch 
Laboratories.  
Immunoprecipitation 
Briefly, soluble protein extracts were prepared from 293T cells transiently transfected with 
HA-VPRBP and Myc-FOXM1 (wild type or mutants). Cell were lysed in NETN as described 
above. Precipitation was performed by rotating 50 μl of EZview™ Red Anti-HA Affinity Gel or 
EZview™ Red Anti-c-Myc Affinity Gel (Sigma) with 2 mg of soluble, clarified lysate overnight 
at 4 °C. The affinity resin was recovered by centrifugation at 1,000 × g for 1 minute and washed 3 
times with ice-cold lysis buffer. Precipitates were eluted in SDS-PAGE buffer and analyzed by 
immunoblot.  
RT-qPCR 
 Total RNA was isolated with an RNeasy Plus mini Kit (Qiagen) and then reverse 
transcribed with a SuperScript® III First-Strand Synthesis System (Invitrogen). The resulting 
complementary DNA was used for quantitative PCR with iTaq™ Universal SYBR® Green 
Supermix (Bio-Rad). Data was normalized to GAPDH. Real-time PCR and data collection were 
done with a QuantStudio 6 Flex Real-Time PCR System and Software (Applied Biosystems). All 
of the primers sequences used for RT-qPCR analysis, ChIP and site directed mutagenesis are 
described in Table 2.2. 
Luciferase Reporter Assays 
The FOXM1 6xDB luciferase reporter was a kind gift from Michael Whitfield (Dartmouth 
University). 293T cells grown on 12-well plates were transiently transfected with 6xDB reporter 
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in combination with different constructs (FOXM1, MELK and VPRBP) using PolyJet Plus 
transfection reagent (SignaGen Laboratories). The MELK expression vector was a kind gift from 
Lee Graves (University of North Carolina). The Nrf2 expression vector and Nrf2 luciferase 
reporter were gifts from Ben Major (University of North Carolina). VPRBP expression vectors 
were a kind gift from Yue Xiong (University of North Carolina). Cells were routinely collected at 
48 h post-transfection. Luciferase activity was measured using the luciferase reporter assay system 
(Promega). Experiments were performed in three technical replicates each. Statistical differences 
were determined using Student's t test.  
Flow Cytometry 
For cell cycle profiling, trypsinized cells were washed with phosphate-buffered saline 
(PBS), fixed in cold, 70% ethanol and stored overnight at −20°C. DNA was stained for 30 minutes 
in 25 μg/ml propidium iodide and 100 μg/ml RNase A. Samples were analyzed using CyAn flow 
cytometer (Beckman Coulter) and FlowJo X software.  
In Vivo Ubiquitination Assay 
293T cells were co-transfected with 6xHIS-Ubiquitin and HA-VPRBP, with or without 
Myc-FOXM1. 48 h after transfection, cells were lysed in denaturing buffer, mixed and sonicated. 
Samples were incubated with equilibrated HisPur™ Ni-NTA Resin (ThermoFisher) overnight at 
4˚C on a rotator. After repeated washing, the resin was eluted with SDS-PAGE sample buffer. 
Detailed experimental procedures describing the wash and lysis buffers are described in (247). 
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Expression and Binding Assay for VPRBP and FOXM1c 
VPRBP was expressed from pcDNA3 using the PURExpress® system supplemented with 
35S-methionine according to the manufacturer protocol. Full-length FOXM1c (1-763) was 
subcloned into pET-28b, producing a c-terminally 6xHIS-tagged clone, and expressed in 
Escherichia Coli BL21(DE3) cells. Protein expression was induced with isopropyl-b-D-
thiogalactopyranoside (IPTG) (250 uM) at 17°C for 18 h. The pellet was sonicated in 40 mL of 
Lysis Buffer (20 mM KH2PO4 pH 7.5, 500 mM NaCl, 10 mM Imidazole, 1 mM Tris(2-
carboxyethyl)phosphine (TCEP), 10% glycerol, 2 mM phenylmethylsulfonyl fluoride (PMSF), 1 
protease tablet, 5 mM MgCl2, 40 units of DNase I). Lysis supernatant was loaded on a 5 mL 
HisTrapä HP column, washed with Buffer A (20 mM KH2PO4 pH 7.5, 500 mM NaCl, 10 mM 
Imidazole, 1 mM TCEP, 10% glycerol), and eluted with Buffer B (20 mM KH2PO4 pH 7.5, 500 
mM NaCl, 500 mM Imidazole, 1 mM TCEP, 10% glycerol). Protein fractions were pooled and 
desalted with a 200 mL HiPrepä 26/10 column into Buffer C (20 mM KH2PO4 pH 7.5, 200 mM 
NaCl, 10 mM Imidazole, 1 mM TCEP).  
Nickle-charged nitrilotriacetic acid (Ni-NTA) resin was prepared with wash buffer (20 mM 
KH2PO4 pH 7.5, 200 mM NaCl, 10 mM Imidazole, 1 mM TCEP, 0.002% Tween-20) and loaded 
with FOXM1c-6xHIS. The column was washed with 3 columns volumes of wash buffer and 
purified VPRBP was added to the resin for 1 h at 4°C. The resin was washed and eluted (using 20 
mM KH2PO4 pH 7.5, 200 mM NaCl, 500 mM Imidazole, 1 mM TCEP, 0.002% Tween-20) at 
75°C and samples visualized by autoradiography. 
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Figure 2.1 FOXM1 is regulated by CUL4, DDB1 and VPRBP. A. Illustration of CRL4 complex. DDB1 bridges 
either CUL4A or CUL4B to substrate adaptor subunits termed DCAF or DWD proteins. Substrates are ubiquitylated 
by E2 enzymes that are recruited to the cullin backbone by RBX1 or RBX2. B. FOXM1 scored in a GPS screen for 
CRL4 substrates. Three independent microarray probes were shifted in response to dominant-negative CUL4 
treatment. C. U2OS cells treated with MLN4924 for 4 h and analyzed by IB. D. U2OS cells were treated with siRNAs 
targeting FF (control), DDB1, CUL4A or CUL4B and analyzed by IB after 72 h. E. Same as in D. but performed in 
U2OS cells stably expressing Myc-FOXM1. F. U2OS and HeLa cells treated with siRNAs targeting FF or VPRBP 
and analyzed by IB after 72 h. G. U2OS cells treated with siRNAs targeting FF or VPRBP were synchronized in S 
phase using thymidine. Cycloheximide (CHX) was added 4 h after release into the cell cycle and FOXM1 stability 
was assessed by IB. 
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Figure 2.2 FOXM1 is regulated by VPRBP. A. 293T cells treated with MLN4924 and analyzed by IB. B. U2OS 
cells treated with siRNAs targeting FF or VPRBP were synchronized in S phase using thymidine. Following release 
into the cell cycle for indicated times, FOXM1 abundance was analyzed by IB. C. Same as B. Two independent 
oligonucleotides were used to deplete VPRBP. FOXM1 abundance was analyzed by IB 4 h after thymidine release. 
D. HCT116 cells were synchronized throughout the cell cycle after VPRBP depletion. FOXM1 abundance was 
analyzed by IB. E. U2OS cells were treated with cycloheximide (CHX) and analyzed by IB at the indicated times. F. 
The stability of a mutant Myc-FOXM1 with five amino acid substitutions in the putative degron sequence was analyze 
by IB. G. The stability of mutant Myc-FOXM1 with indicated amino acid substitutions was analyzed by IB following 




Figure 2.3 VPRBP binds and ubiquitylates FOXM1 in vivo. A. HA-VPRBP and Myc-FOXM1 were transiently 
expressed in 293T cells. VPRBP was recovered on anti-HA-agarose and analyzed by IB. Cells were treated with 
MG132 prior to lysis. B. Endogenous FOXM1 was precipitated from a 293T cells extract and analyzed by IB. C. 
Bacterially purified 6HIS-FOXM1 was incubated with in vitro produced, [35S]methionine-labeled VPRBP. 
Flowthrough and eluates after pulldown were analyzed by autoradiography. D and E. 6HIS-ubiquitin was 
transiently expressed in 293T cells with and without HA-VPRBP. 6HIS-ubiquitin was recovered after lysis under 
strong denaturing conditions and analyzed by IB. Analysis of either endogenous (D) or exogenously expressed (E) 
Myc-FOXM1 was done by IB. (F) Crystal structure from Schwefel et al. depicting the interaction between VPRBP 
and SAMHD1. Alignment of similar residues between SAMHD1, FoxM1, and two other VPRBP substrates (TET2 
and MCM10) is shown below. G. Amino acid substitutions were made in a FOXM1 fragment (aa 321 to 480) 
corresponding to the residues found in the VPRBP-SAMHD1 interface. Binding was analyzed as described for (A) 
between Myc-FOXM1321–480 and HA-VPRBP. H. The stability of Myc-FOXM1321–480 fragments that were impaired 
in their binding to VPRBP was analyzed by CHX chase. 
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Figure 2.4 Examining the FOXM1-VPRBP interaction. A. HA-VPRBP and Myc-FOXM1 were transiently 
expressed in 293T cells. VPRBP was recovered on HA-agarose following lysis and analyzed by IB. Cells were 
treated with or without MG132 prior to lysis. B. Fragments of FOXM1 were transiently expressed with a Myc tag in 
combination with HA-VPRBP in 293T cells. VPRBP was recovered on HA-agarose following lysis and analyzed by 
IB. Cells were treated with MG132 prior to lysis. C. Fragments of FOXM1 were transiently expressed with a Myc-
tag in combination with HA-VPRBP in 293T cells. FOXM1 and the indicated fragments were recovered on Myc-
agarose following lysis and analyzed by IB. Cells were treated with MG132 prior to lysis. 
 
 49 
Figure 2.5 VPRBP activates the FOXM1 6xDB transcriptional reporter. A. FOXM1 and VPRBP were 
expressed in 293T cells in combination with the 6xDB reporter. Luciferase activity (RLA) was measured 48h after 
transfection. Error bars represent SD of triplicates. B. Combinations of MELK, FOXM1 and VPRBP were expressed 
in 293T cells with the 6xDB reporter. Luciferase activity was measured 48h after transfection. Error bars represent 
SD of triplicates. C. High and low concentrations of VPRBP were expressed in 293T cells with the 6xDB reporter. 
At 24 and 48h after transfection identical populations of cells were measured for luciferase activity (C1) and 
harvested and split for analysis by IB (C2) and cell cycle analysis by propidium iodide staining (C3). Luciferase 




Figure 2.6 VPRBP regulates FOXM1 independent of binding to the CRL4 complex. A. A NRF2 luciferase 
reporter was expressed in 293T cells in combination with either FOXM1, VPRBP or NRF2. B. U2OS cells treated 
with siRNAs targeting FF, FOXM1, VPRBP were synchronized in mitosis by treatment with nocodazole. Mitotic 
cells were isolated by shake-off and the expression of FOXM1 target genes was analyzed using RT-qPCR. Errors 
bars show SD of triplicates. C. VPRBPWT and mutant versions that cannot bind DDB1 (RARA and N909) were 





Figure 2.7 VPRBP depletion reduces FOXM1 target gene expression and the number of mitotic cells. A. 
U2OS cells treated with siRNAs targeting FF or VPRBP were synchronized in G2/M using a thymidine block and 
release. The FOXM1 target genes were analyzed using RT-qPCR. Error bars represent SD of triplicates. B. U2OS 
cells treated with siRNAs targeting FF or VPRBP were fixed and immunostained for phosphor-histone H3 serine 10 
(P-H3S10). DNA was counterstained with Hoechst. Images were captured using an automated imaging system and 
the percentage of P-H3S10 positive cells was calculated and averaged from six, wide-field images for each 













Figure 2.8 VPRBP associates with FOXM1 promoters and activates FOXM1 independent of CUL4. A. U2OS 
cells were synchronized in G2/M phase and fixed for ChIP analysis with control IgG, FOXM1 and VPRBP 
antibodies. VPRBP associated with the promoters of some FOXM1 target genes. B. VPRBPWT and mutant versions 
that cannot bind DDB1 (RARA and N909) were expressed in 293T cells in combination with the 6xDB reporter. 
Luciferase activity was measured 48 h after transfection. Error bars represent SD of triplicates. C. HA-VPRBP was 
transiently expressed in 293T cells which were subsequently treated with nocodazole or vehicle control (DMSO). 
VPRBP was recovered or HA-agarose following lysis and analyzed by IB. D. HA-VPRBP and Myc-FOXM1 were 
transiently expressed in 293T cells which were subsequently treated with nocodazole or vehicle control (DMSO). 













Figure 2.9 Implications and cell cycle control and malignancy. A. Ovaries resected from patients with HGSOC 
were blotted for VPRBP and compared to normal ovaries. Dotted line indicates splicing together of samples run on 
the same gel. B. Graphical depiction of model described by data. Our data suggests that VPRBP contributes to the 
degradation and activation of FOXM1. VPRBP binds to the CRL4 ligase complex and targets FOXM1 for 
degradation from S-phase. During G2/M phases, when FOXM1 activity peaks, VPRBP disengages from CRL4 and 








Antigen Source Animal Company Cat. # Dilution Use 
FOXM1 rabbit Santa Cruz sc-502 1:2000 Immunoblot 
VPRBP rabbit Proteintech 11612-1-AP 1:1000 Immunoblot 
CUL4A rabbit Abcam ab72548 1:1000 Immunoblot 
CUL4B rabbit Sigma-
Aldrich 
HPA011880 1:1000 Immunoblot 
DDB1 rabbit Bethyl A300-462A 1:1000 Immunoblot 
GAPDH rabbit Santa Cruz sc-25778 1:5000 Immunoblot 
Ran mouse BD 
Biosciences 
610340 1:10000 Immunoblot 
Myc mouse Santa Cruz sc-40 1:2000 Immunoblot 
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AAACCGCGTCTAGCATTAGC CENPF Fwd Primer for RT-qPCR (FOXM1 ChIP)
CTCCACGCCTATTGGTCACT CENPF Rev Primer for RT-qPCR (FOXM1 ChIP)
AGTCTACGGGCTACCCGATT CDK1 Fwd Primer for RT-qPCR (FOXM1 ChIP)
AGCCACTGTACCCGGCTTAT CDK1 Rev Primer for RT-qPCR (FOXM1 ChIP)
AACCACGCCCTCCATCTAC FZR1 Fwd Primer for RT-qPCR (FOXM1 ChIP)
CCCGCGATTCAAATCAATAC FZR1 Rev Primer for RT-qPCR (FOXM1 ChIP)
GGCAAGCAGTTAGGCTTCTG PTMS Fwd Primer for RT-qPCR (FOXM1 ChIP)
CGGTCACCTCCACTCCTCT PTMS Rev Primer for RT-qPCR (FOXM1 ChIP)
TGGGAAGGCAGAACCAGAATC XRCC1 Rev Primer for RT-qPCR (FOXM1 ChIP)
GGGAAGGTGAGAAAACAGGGTG XRCC1 Rev Primer for RT-qPCR (FOXM1 ChIP)
CATAAGGGGGCAGAATAAGAGTTG BRCA2 Fwd Primer for RT-qPCR (FOXM1 ChIP)
TGATAGAAGGTGGAAATGAGGTCC BRCA2 Rev Primer for RT-qPCR (FOXM1 ChIP)
TTCACCTGCTGTGCATTCTC VPRBP forward primer for real-time PCR
CAAAGGCTGGCTCCAAGTAG VPRBP reverse primer for real-time PCR
TTCCAGTTATGCAGCACCT CCNB1 Fwd Primer for real-time PCR
ACTTGTTCTTGACAGTCATGTG CCNB1 Rev Primer for real-time PCR
GGCCTCCAAGGAGTAAGACC GAPDH forward primer for real-time PCR
AGGGGTCTACATGGCAACTG GAPDH reverse primer for real-time PCR
GCAGCAAAGATCAATTGAAG CENPF Fwd Primer for real-time PCR
TTTCCACCTGGTCTTTGTG CENPF Rev Primer for real-time PCR
CTCACCAGAAACGATGGTG CDC25B Fwd Primer for real-time PCR
GGTATCTGCAGTCTACAATCAC CDC25B Rev Primer for real-time PCR
GACAAGTACGGCCTTGGGTA PLK1 forward primer for real-time PCR
GTGCCGTCACGCTCTATGTA PLK1 reverse primer for real-time PCR
CATAGCAAGCGAGTCGCGGCCGCCCCCAAGGTTTTT forward primer for cloning RI418AA into full length FOXM1C
AAAAACCTTGGGGGCGGCCGCGACTCGCTTGCTATG reverse primer for cloning RI418AA into full length FOXM1C
CGAGTCCGCATTGCCCCCGCTGTGCTGCTAGCTGAGGAG forward primer for cloning K422 into full length FOXM1C  
CTCCTCAGCTAGCAGCACAGCGGGGGCAATGCGGACTCG reverse primer for cloning K422 into full length FOXM1C 
GCAGCTAGATCGTTGGGAAG MYC ECR1 forward primer for real-time PCR (ChIP)














CHAPTER 3: FOXM1 DEUBIQUITINATION BY USP21 REGULATES CELL CYCLE 




 FOXM1 is a member of the forkhead box family of transcription factors, comprised of 44 
members in humans, all of which share a conserved forkhead DNA-binding motif (248, 249). 
FOX family transcription factors are involved in numerous processes, and play particularly 
important roles in stem cell differentiation, proliferation, cell cycle, and metabolism (150). 
FOXM1 is best known for its role in regulating the cell cycle, primarily through the transcription 
of a set of targets involved in establishing a timely entry and progression through mitosis (156, 
170, 211, 217), and ensuring chromosome stability (211). In addition to its important role in 
normal cell cycles, the periodically expressed cell cycle genes controlled by FOXM1 are 
significantly upregulated in specific cancers and cancer subtypes (190, 214, 250). 
 Breast cancers are stratified into five subtypes based on molecular features and 
transcriptome-based analysis which predict outcomes and guide treatment paradigms. The 
molecularly-defined basal-like breast cancer (BLBC) subtype largely overlaps with the triple-
negative classification, named due to a lack of overexpression of oestrogen receptor (ER), 
progesterone receptor (PR), and HER2 genes (251, 252). Outside of mutations to TP53, 
                                               
2 This chapter previously appeared as an article in Cell Reports. The original citation is as follows: A. Arceci, T. 
Bonacci, X. Wang, K. Stewart, J.S. Dramrauer, K.A. Hoadley, M.J. Emanuele. FOXM1 Deubiquitination by USP21 
Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer. Cell Rep. 26, 3076–3086.e6 
(2019). 
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occurring in 80% of patient tumors, BLBC lacks recurrent somatic mutations to known 
oncogenes, and instead exhibits a high degree of chromosome instability in the form of copy-
number gains and losses as well as severe aneuploidy (190, 250). Upregulation of the FOXM1 
transcriptional signature represents a defining feature of the BLBC subtype, as well as other 
related malignancies, such as high-grade serous ovarian cancer (214). Despite the upregulation of 
FOXM1 in BLBC, it is largely unknown how FOXM1 is activated in patient tumors. Due to its 
roles in the promotion of both cancer and chemotherapy resistance (195, 253), FOXM1 
represents an attractive anti-cancer treatment target (254). 
FOXM1 is cell cycle regulated, with peak expression and activity occurring during G2/M 
phase (147). FOXM1 is controlled by a variety of post-translational modifications, including 
phosphorylation (161, 172, 173) and SUMOylation (175, 176), however, it is unclear how these 
might account for its upregulation in cancer. Ubiquitination also plays an important role in FOXM1 
regulation. FOXM1, and many of its transcriptional targets are ubiquitinated by the anaphase-
promoting complex/cyclosome (APC/C), thereby triggering their degradation following the onset 
of mitosis (153, 237). Ubiquitination of FOXM1 by CUL4VPRBP (255), RNF168 (182), SCFFBXO31 
(181) and SCFFBXW7 (256) has also been reported. Together, this points to a pivotal role for 
ubiquitination dependent degradation in regulating FOXM1. 
A potential strategy for inactivating FOXM1 may exist through targeting enzymes which 
prevent FOXM1 destruction. To that end, we sought to identify deubiquitinating enzymes (DUBs) 
that regulate FOXM1 stability through the removal of ubiquitin, thus protecting FOXM1 from 
degradation. DUBs are catalytic proteases which remove ubiquitin from substrates with high in 
vivo selectivity. The human genome encodes approximately 100 DUBs, which are grouped into a 
 58 
growing number of subfamilies (53). Notably, several selective small-molecule DUB inhibitors 
have been developed, pointing to their potential druggability (257, 258). 
By deploying an RNAi-based screen against nucleus-localized DUBs, Ubiquitin-Specific 
Protease 21 (USP21) was identified as a potential regulator of FOXM1 stability. USP21 is a 
member of the Ubiquitin Specific Protease (USP) family of DUBs which contains 56 members 
unified by a highly conserved USP domain, featuring a catalytic triad essential for activity (53). 
USP21 has been linked to transcriptional regulation through interaction with the transcription 
factors NANOG (77), GATA3 (75), GLI1 (76) as well as histone H2A (73). 
Here, we demonstrate a substrate-enzyme relationship between FOXM1 and USP21. 
USP21 regulates FOXM1 abundance and USP21 binds and removes polyubiquitin chains from 
FOXM1, thus protecting it from proteasomal degradation. We also show that USP21 expression 
can alter the FOXM1 transcriptional network which has consequences in regulating mitotic timing 
and proliferation. Furthermore, we show that FOXM1 and USP21 are specifically upregulated in 
BLBC and that depletion of USP21 can improve sensitivity to paclitaxel, primarily through its 
relationship with FOXM1. These findings demonstrate that USP21, through the maintenance of 
FOXM1 stability, regulates cell cycle progression and that inhibiting USP21 has therapeutic 
potential in treating BLBC with a FOXM1-high, USP21-high expression signature. 
 
Results 
USP21 Binds and Alters FOXM1 Abundance 
To determine if FOXM1 abundance is regulated by deubiquitinating enzyme (DUB) 
activity, HeLa cells were treated with PR-619, a small-molecule, non-specific pan-DUB inhibitor 
for 8 hours. Immunoblot (IB) analysis revealed that FOXM1 abundance significantly decreased 
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with increasing concentrations of PR-619 (Figure 3.1A). This suggested that the degradation of 
FOXM1 could be actively prevented by DUBs. 
To discover specific USP-family DUBs which directly affect FOXM1 abundance, HeLa 
cells were transfected with pooled siRNAs against a subset of USP-family DUBs which show 
nuclear localization. IB analysis of cell lysates 48 hours after transfection revealed that USP21 
knockdown reproducibly reduced the level of endogenous FOXM1 (Figure 3.1B). Deconvolution 
of the siRNA pool revealed that multiple, independent siRNAs reagents targeting USP21 reduced 
the protein levels of FOXM1 (Figure 3.2A). Furthermore, FOXM1 abundance was not 
significantly reduced in cells stably expressing a FLAG-HA-tagged USP21 variant made resistant 
to USP21 siRNA (Figure 3.2B), demonstrating that the reduction in FOXM1 abundance is 
specifically linked to an on-target effect of USP21 knockdown.  Correspondingly, ectopic 
expression of USP21 significantly increased FOXM1 abundance in 293T cells (Figure 3.1C). 
These results demonstrate that FOXM1 abundance is regulated by USP21.  
To determine if the effects on FOXM1 stability resulting from changes of USP21 
expression were due to an interaction between the two proteins, FLAG- or HA-tagged FOXM1b 
and Myc-USP21 plasmids were ectopically expressed in 293T cells. An interaction between 
FOXM1 and USP21 was detected by co-immunoprecipitation (co-IP), regardless of whether the 
IP was directed against Myc-USP21 (Figure 3.1D) or HA-FOXM1b (Figure 3.1E). Additionally, 
an interaction between endogenous FOXM1 and USP21 was detected using antibodies directed 
against USP21 (Figure 3.1F). To determine the domain on FOXM1 recognized by USP21, a series 
of Myc-FOXM1b fragments (Figure 3.2C) were co-transfected with FLAG-HA-USP21 into 293T 
cells and interactions were assessed by co-IP. Results from IP directed against both Myc-FOXM1b 
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(Figure 3.2D) and FLAG-HA-USP21 (Figure 3.2E) demonstrate that USP21 binds to a region 
encompassing FOXM1 amino acids 321-400. 
Since exogenous and endogenous FOXM1 and USP21 can interact in vivo, we assessed 
their binding in vitro by incubating recombinant, bacterially-produced hexa-histidine (6xHIS) 
tagged FOXM1b with recombinant, bacterially-produced GST-tagged USP21. 6xHIS-FOXM1b 
was detected in complex with GST-USP21 following pulldown on glutathione resin (Figure 3.1G). 
Taken together, these data demonstrate that USP21 and FOXM1 directly interact, strongly 
suggesting an enzyme-substrate relationship between the two proteins. 
FOXM1 is a USP21 Substrate 
 FOXM1 is a known substrate of several E3-ubiquitin ligases, including APC/C (153, 
237) and CUL4VPRBP (255), which can conjugate polyubiquitin chains onto FOXM1, triggering 
its subsequent proteasomal degradation. To determine if the effects that USP21 knockdown or 
overexpression has on FOXM1 are mediated through proteasomal degradation, HeLa cells 
transfected with siFF (control) or siUSP21 were treated with the proteasome inhibitor MG132. 
IB analysis confirms that FOXM1 destabilization resulting from USP21 knockdown is partially 
rescued through proteasome inhibition (Figure 3.3A). 
DUBs oppose proteasomal degradation through removal of polyubiquitin chains, 
particularly K48 and K11 topologies and USP21 has been shown to cleave both of these 
polyubiquitin linkages in vitro (68). To determine if USP21 influences polyubiquitin chain 
conjugation on FOXM1, we analyzed FOXM1 ubiquitination in vivo. 293T cells were 
transfected with HA-FOXM1b and 6xHIS-FLAG-ubiquitin in combination with either wild-type 
USP21 (USP21WT) or a catalytically-dead variant of USP21 (cysteine at amino acid position 221 
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changed to alanine; USP21C221A). 24 hours post-transfection, cells were harvested and lysed 
under denaturing conditions, subjected to pulldown on Ni-NTA resin to enrich for ubiquitinated 
proteins and analyzed by IB. Polyubiquitinated FOXM1 (FOXM1 ≥100kDa on top panel of 
Figure 3.3B) was readily detectable under conditions with endogenous levels of USP21 
expression (Figure 3.3B, lane 2), but was greatly diminished by overexpression of USP21WT 
(Figure 3.3B, lane 3). However, levels of polyubiquitinated FOXM1 were restored close to levels 
observed in control conditions when USP21C221A was overexpressed (Figure 3.3B, lane 4). 
Similarly, USP21WT, but not USP21C221A, immunopurified from 293T cells reduced 
polyubiquitination of FOXM1 isolated from proteasome inhibitor treated 293T cells, in an in 
vitro deubiquitination assay (Figure 3.4A). 
Since USP21 can directly bind and deubiquitinate FOXM1, we next evaluated the impact 
of USP21 on FOXM1 stability. To assess the effect of USP21 on FOXM1 half-life, FOXM1 
levels were assessed by IB following overexpression of either USP21WT or USP21C221A in 293T 
cells (Figure 3.3C) and depletion of USP21 in BLBC MDA-MB-231 cells (Figure 3.4B) treated 
with cycloheximide to block protein translation. Interestingly, FOXM1 abundance decreases 
with similar kinetics over the first 4 hours following cycloheximide treatment in all conditions, 
but USP21WT overexpression can protect the remaining population from degradation for at least 
another 12 hours whereas FOXM1 abundance falls even more rapidly in USP21C221A cells than 
control after this point (Figure 3.3C). Half-life quantified from the best-fit curve for FOXM1 in 
control cells is approximately 7.6 hours. The expression of USP21WT increased FOXM1 stability, 
and its half-life was approximately 12.4 hours. In contrast, ectopic expression of USP21C221A 
shortened FOXM1 half-life to approximately 3.7 hours, consistent with it having a dominant-
negative effect on FOXM1 stability as well as controlling its own ubiquitination (Figure 3.4B). 
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Similarly, depletion of USP21 in MDA-MB-231 reduced FOXM1 half-life from 11.5 hours to 
4.2 hours (Figure 3.4C). Taken together, these results indicate that USP21 controls FOXM1 
ubiquitination and proteasomal-mediated degradation. 
USP21 Affects the FOXM1 Transcriptional Network and Proliferation 
FOXM1 is the master transcriptional regulator of a set of genes which are involved in 
establishing and ensuring a successful G2/M transition and progression through mitosis. 
Dysregulation of this transcriptional network has been shown to induce cell cycle delays, mitotic 
defects, and mis-segregation of chromosomes (211).  
We hypothesized that modulating USP21 levels would have corresponding effects on 
FOXM1 transcriptional output due to its effects on stabilizing FOXM1. To determine the effect 
that USP21 overexpression has on FOXM1 activity, 293T cells were co-transfected with USP21 
and a FOXM1 luciferase-based transcriptional activity reporter (6X-DBE) (259). USP21 
overexpression significantly enhanced FOXM1-dependent transcriptional activity compared to 
control (Figure 3.5A). This is consistent with our previous data demonstrating that FOXM1 
abundance is positively enhanced by USP21 overexpression. Correspondingly, a panel of 
FOXM1 transcriptional targets was assessed by RT-qPCR following siRNA transfection to 
knockdown either FOXM1 or USP21 in MDA-MB-231 cells. Knockdown of USP21 leads to a 
reduction in all FOXM1 transcriptional targets assessed compared to controls (Figure 3.5B, 
compare red bars to black bars). USP21 knockdown did not lead to the same decrease in FOXM1 
transcriptional target abundance as FOXM1 knockdown (Figure 3.5B, compare red bars to 
orange bars), however this is consistent with biochemical data demonstrating that USP21 
knockdown reduces FOXM1 levels to an amount between what is observed in control and 
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FOXM1 knockdown conditions (Figure 3.5C). Additionally, USP21 overexpression did not 
significantly alter FOXM1 mRNA levels in MDA-MB-231 cells transduced with a 
pINDUCER20 lentivirus to introduce a doxycycline-inducible USP21 transgene (260) (Figure 
3.6A). Taken together, these data demonstrate that changes in FOXM1 levels due to USP21 have 
downstream effects on the FOXM1 transcriptional network. 
 Tight regulation of the FOXM1 transcriptional network is required for a timely and high-
fidelity transition from G2 to mitosis. Having demonstrated that USP21 levels can affect the 
FOXM1 transcriptional network, we next sought to determine if the kinetics of mitotic entry are 
disrupted by USP21 loss. To observe effects on mitotic timing, the accumulation of phospho-
histone H3 S10 (P-H3) following release of cells from synchronization at the G1/S boundary with 
aphidicolin was monitored in MDA-MB-231 cells depleted of FOXM1 or USP21. In parallel, we 
also analyzed cells where FOXM1 was ectopically expressed in USP21-depleted cells (Figure 
3.6B). Following release from synchronization, cells were treated with the microtubule poison 
nocodazole so that they would get trapped in mitosis, allowing us to determine the percent of 
cells that had entered mitosis throughout the duration of the experiment. Depletion of either 
FOXM1 or USP21 significantly impaired cell cycle progression into mitosis. 22 hours after 
release only 1.6% and 10.9% of cells were P-H3 positive, in FOXM1 and USP21-depleted 
populations, respectively (Figure 3.5D). In contrast, 40.7% of control cells had entered mitosis 
by that time. Interestingly, mitotic entry was significantly rescued (27.4% P-H3 positive) in the 
USP21-depleted/FOXM1 overexpression populations. These results confirm prior reports that 
FOXM1 knockdown impairs mitotic entry (211). Furthermore, they demonstrate that USP21 
promotes progression through mitosis since its depletion severely impairs the accumulation of 
mitotic cells. Since this defect is largely rescued by forced FOXM1 expression, this indicates that 
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the cell cycle phenotype in USP21-depleted cells occurs largely due to the reduction of FOXM1 
abundance. 
Finally, we hypothesized that slowed mitotic entry resulting from FOXM1 and USP21 
knockdown would cause a corresponding reduction in proliferation. Indeed, proliferation was 
significantly impaired in the BLBC cell lines MDA-MB-468 and MDA-MB-231 (Figure 3.5E). 
In addition, ectopic, doxycycline-inducible expression of FOXM1b in MDA-MB-231 cells 
partially rescued the impaired proliferation caused by USP21 depletion. Similar results were 
observed in HeLa cells over a four-day period (Figure 3.6C). Thus, downregulation of USP21 
can affect overall proliferation by downregulating both FOXM1 stability and the downstream 
effects of the FOXM1 transcriptional network. 
USP21 Amplification Correlates with FOXM1 Protein Levels and Tumor Proliferation in BLBC 
 FOXM1 upregulation has been reported in a variety of cancers (159, 190, 214, 261, 262). 
Notably, in breast cancer, we found that FOXM1 mRNA expression is significantly correlated 
with breast cancer subtypes, showing the highest expression in the BLBC subtype (t-test basal 
versus non-basal, p ≤ 2.2 x 10-16) (Figure 3.7A, top panel). This is consistent with prior genomic 
studies which found the FOXM1 transcriptional signature upregulated in BLBC (190). We next 
analyzed the proliferative capacity of tumors where FOXM1 is activated. Remarkably, the 
proliferation score of individual tumors was highly and significantly correlated with FOXM1 
expression, both across all breast cancer subtypes, as well as within individual subtypes. That is, 
a tumor proliferation score increases as a function of FOXM1 mRNA expression among all 
patient breast tumors even within only the luminal A breast cancers (Figure 3.7A, top panel, blue 
dots) which generally proliferate more slowly than more aggressive HER2-enriched and BLBC 
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subtypes. As expected, expression analysis of well-established FOXM1 transcriptional targets 
revealed a corresponding upregulation in FOXM1-high, BLBC patient samples (Figure 3.7A, 
bottom panel). We conclude that FOXM1 expression and activity exists on a sliding scale, with 
increasing FOXM1 levels alone being a strong indicator of tumor proliferation. 
 Next, we analyzed copy number changes and mRNA expression for all human DUBs 
among breast tumors in the TCGA dataset. USP21 is the fourth-most frequently CNA-amplified 
and the most frequently mRNA-overexpressed DUB across all patient samples (Figure 3.7B) 
with USP21 amplification being significantly correlated with both proliferation score and the 
BLBC subtype (Figure 3.9A). The genomic location of USP21 is 1q23. Strikingly, this region is 
the most frequently amplified region in BLBC patient tumors (85, 263). However, this amplicon 
lacks a well-described oncogene which contributes to disease. Correspondingly, IB analysis of 
FOXM1 and USP21 protein expression in cell lines representing the normal-like, luminal, and 
BLBC subtypes of breast cancer revealed that FOXM1 and USP21 expression are uniquely high 
in the BLBC subtypes (Figure 3.7C, Figure 3.9B). 
 FOXM1 is among the 227 proteins/antigens profiled by reverse phase protein array 
(RPPA) in TCGA. This provided us the opportunity to examine the abundance of FOXM1 
protein levels in breast cancer, and its relationship to USP21 mRNA expression in tumors. Since 
our results demonstrate that the FOXM1 protein is post-translationally stabilized by USP21, we 
examined FOXM1 protein levels as a function of USP21 expression. Remarkably, FOXM1 
protein is the most significantly upregulated protein/antigen in USP21-amplified tumors (Figure 
3.7D). Among the other most statistically significant increasing proteins were the FOXM1 
targets cyclin B1, the cell cycle regulated gene MSH6 (264), adenosine deaminase ADAR1 
(which is proximal to the genetic location of USP21), and the asparagine deaminase, ASNS, 
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which has been previously implicated in breast cancer proliferation and cell cycle progression 
(265). Since FOXM1 is upregulated by USP21, we asked if a curated list of 114 FOXM1 target 
genes are correlated with USP21 amplification using gene set enrichment analysis (GSEA). This 
analysis revealed a strong enrichment for the FOXM1 transcriptional network in USP21 
amplified breast cancers (Table 3.1). 
USP21 Affects Paclitaxel Response in Basal-like Breast Cancer 
In addition to its role in cancer proliferation, high FOXM1 expression has been attributed 
to resistance to platinum-based drugs (253) and taxanes (195, 266) in breast cancer and 
correlated with metastasis and poor patient outcomes. Having identified FOXM1 as a USP21 
substrate, we examined if USP21 knockdown could increase sensitivity to paclitaxel in a 
FOXM1-dependent manner. The BLBC cell lines MDA-MB-231 and MDA-MB-468 and 
SUM149 cells were used to assess viability following 72 hours of exposure to DMSO or 
paclitaxel in control (siFF), FOXM1-depleted (siFOXM1) and USP21-depleted (siUSP21) cells. 
In addition, in MDA-MB-231 cells we utilized a cells line containing a stably integrated, 
doxycycline inducible version of FOXM1, allowing us to examine viability in USP21-depleted / 
FOXM1-induced (siUSP21 + FOXM1b) conditions. Across all cell lines assessed, there is a 
significant reduction in viability between FOXM1 and USP21-depleted conditions treated with 
paclitaxel compared to the same depletion condition where cells were not treated with paclitaxel 
(DMSO control; Figure 3.8A). Therefore, while depletion of USP21 (and FOXM1) impairs 
proliferation in each of these cell lines under control conditions, there is a statistically significant 
decrease in viability when USP21 depletion is combined with paclitaxel treatment. Specifically, 
in MDA-MB-231 cells exposed to paclitaxel, cell viability was reduced by 40.9% and 38.3% 
compared to control in FOXM1 and USP21-depleted conditions, respectively (Figure 3.8A, top 
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panel). However, cell viability is only reduced by 16.7% in cells where USP21 was depleted but 
FOXM1 levels are restored with doxycycline induction. In MDA-MB-468 cells treated with 
paclitaxel, viability was more strongly reduced by 81.3% and 41.5% compared to control in 
FOXM1 and USP21-depleted conditions, respectively (Figure 3.8A, middle panel). Finally, in 
SUM149 cells treated with paclitaxel, viability was significantly reduced by 43.6% and 20.2% in 
FOXM1 and USP21-depleted conditions respectively (Figure 3.8A, bottom panel). This is 
particularly striking considering that SUM149 cells do not show a significant reduction in 
viability when treated with paclitaxel alone. The significant difference in cell viability resulting 
from FOXM1 depletion and USP21 depletion combined with a significant rescue of viability 
when FOXM1 is overexpressed in the USP21-depleted conditions suggests that FOXM1 
significantly contributes to paclitaxel sensitivity and is a critical USP21 substrate, although 
perhaps not the only one, contributing to the differences in paclitaxel sensitivity observed in 
USP21-depleted cells. 
Based on the realization that USP21 depletion sensitizes cells to paclitaxel, we next 
determined how BLBC cells would respond to paclitaxel following USP21 depletion in a mouse 
xenograft model. SUM149 is a BLBC cell line that is paclitaxel insensitive in mouse xenografts 
(Figure 3.8B, red line). SUM149 were transduced with lentivirus expressing scrambled shRNA 
(shControl) or shUSP21 and implanted in the mammary fat pads of NOD/SCID gamma mice 
following selection for infected cells (Figure 3.9C). Mice were then administered either 
paclitaxel (10mg/kg of bodyweight) or vehicle twice weekly and tumor volume was monitored 
twice weekly for six weeks. The results revealed that average tumor volume was reduced from 
1101.75mm3 in the control condition to 414mm3 (a 62.4% reduction) over six weeks due to 
depletion of USP21 and exposure to paclitaxel (Figure 3.8B, blue line). These results suggest 
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that inhibition of USP21 may provide therapeutic benefit in BLBC by antagonizing proliferation 
and enhancing chemotherapy resistance effects driven by FOXM1 activation. 
 
Discussion 
Here, we identify the transcription factor FOXM1 as a substrate of the deubiquitinating 
enzyme USP21. USP21 stabilizes FOXM1, and suppressing USP21 reduces FOXM1 abundance, 
which subsequently downregulates the FOXM1 transcriptional network. This leads to a mitotic 
entry delay, slowed proliferation and sensitivity to paclitaxel, both in culture and in animal 
xenografts (Figure 3.10). Interestingly, phenotypes linked to USP21 depletion were partially, but 
not completely, mitigated by forced expression of FOXM1. This suggests that FOXM1 is a key 
USP21 substrate with respect to these phenotypes, but likely is not the only target determining 
the role of USP21 in cell cycle, cancer proliferation and paclitaxel sensitivity.  Nevertheless, we 
predict that targeting USP21 could have therapeutic potential in aggressive cancers marked by 
high FOXM1 expression and with concordant genome instability. 
To date, few USP21 substrates have been identified. Many validated substrates, including 
GATA3 (75), GLI1 (76), NANOG (77), and ubiquitinated histone H2A K119 (73) are either 
transcription factors or involved in the regulation of transcription. Our identification of FOXM1, 
a transcription factor that regulates cell cycle progression, as a USP21 substrate supports this 
theme. Given these roles, it is interesting to consider USP21 as a general transcriptional regulator 
through its dual function in stabilizing transcription factors and creating a permissive landscape 
for transcription to occur through the removal of ubiquitin at H2A K119, a post-translational 
modification associated with transcriptional repression. Future work integrating these aspects of 
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transcription under the control of USP21 may underscore its importance in the promotion of 
transcriptional activity. 
BLBC is characterized by having high genomic instability which contributes to a 
distinctive pattern of CNA gains at 1q, 6p, 8q, and 10p along with frequent losses at 4p, 5q, 14q, 
and 15q (267). Outside of TP53 loss, which occurs in more than 80% of cases, there are few 
mutations in well-characterized oncogenes or additional tumor suppressors linked to BLBC. The 
USP21 genomic location is 1q23, an amplified region recently suggested to contain putative 
driver genes for the BLBC subtype (85). The FOXM1 genomic location is 12p13, another 
amplified region associated with the BLBC subtype. Indeed, our analysis supports a link between 
FOXM1 expression, the BLBC subtype, and proliferation as well as a correlation between 
USP21 expression at the genomic and transcriptional level (Figure 3.7B) and a correlation 
between USP21 and FOXM1 levels in BLBC. Notably, we show that USP21 amplification 
correlates with proliferation score of the tumor. While this result is partially complicated by the 
fact that amplification of 1q, and particularly the USP21 genomic locus, is enriched in aggressive 
BLBC subtyped tumors (85), this further points to its potential role in disease. The evidence 
presented here suggests that USP21 could act as a proliferative driver by promoting FOXM1 
stability and transcriptional function which ultimately promotes proliferation in BLBC with 
amplified USP21 and FOXM1 expression. We speculate that increased gene dosage of USP21 
contributes to the proliferative features of BLBC, and that it likely acts coordinately with 
additional proliferative drivers on 1q, as well as with other genes located within recurrently 
altered genomic regions. 
Due to its myriad roles in the promotion and maintenance of cancer, FOXM1 has 
garnered significant attention as a target for therapeutic intervention (158). Since FOXM1 is 
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recurrently activated in specific disease subtypes, including the majority of BLBC and high-
grade serous ovarian cancers, there exists the rationale, therapeutic window, and patient numbers 
to support its therapeutic candidacy. Moreover, while current therapies that target specific 
transcription factors are clinically effective, including hormone therapy in breast cancer and all-
trans retinoic acid (ATRA) in acute promyelocytic leukemia (268), in most cases, transcription 
factors have defied efforts aimed at chemical inhibition (e.g. c-Myc).  
Here, we provide the rationale for an indirect method of downregulating FOXM1 activity 
through the inhibition of USP21. In contrast to transcription factors, DUBs have favorable 
properties which make them attractive therapeutic targets. More specifically, USP-family DUBs 
have deep, active pockets relying on a catalytic triad (53) which is generally tractable with small-
molecule inhibitors (269). Recently, the identification of potent and highly selective USP7 
inhibitors has brought to the forefront the chemical tractability of DUBs as a therapeutic class 
(257, 258). The crystal structure of the USP21 catalytic core has been solved (68) which 
facilitates the identification and development of potent and highly selective small-molecule 
inhibitors through structure-activity relationship studies. Future work describing additional 
substrates and processes influenced by USP21 may uncover additional examples where USP21 
inhibition may demonstrate therapeutic benefit. 
 
Materials and Methods 
Cell Culture 
 Cell lines were all obtained from the American Type Culture Collection, or BioIVT. 293T, 
HeLa, MDA-MB-231, MDA-MB-468, HMEC, MCF7, MCF10A, SUM159, and BT474 cells were 
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cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented with 10% FBS 
(Atlanta Biologicals) and 1% Pen/Strep (Gibco). SUM149 cells were obtained from BioIVT and 
cultured in either F-12 medium (Gibco) supplemented with 5% FBS (Atlanta Biologicals), 10mM 
HEPES pH7.5, 1µg/mL hydrocortisone, 5µg/mL insulin (Gibco) and 1% Pen/Strep (Gibco) or in 
HuMEC Ready Medium (Gibco).  All cells were incubated at 37°C and 5% CO2.  
Transfections and Treatments 
 All siRNA transfections were performed using Lipofectamine RNAiMAX (ThermoFisher) 
following instructions in the manufacturer’s instructions.  Sequence of siRNAs used in this study 
are described in Table 3.2. All plasmid transfections into 293T cells were performed using Mirus 
TransIT-293 reagent (Mirus Bio) following instructions in the manufacturer’s protocol. Plasmid 
transfections into other cell lines were performed using Lipofectamine 2000 (ThermoFisher) 
according to manufacturer’s instructions. PR-619 and MG132 (Selleck Chemicals) were used at a 
concentration of 10µM for 8 hours and 6 hours, respectively. Cycloheximide (MilliporeSigma) 
was used at a concentration of 100ng/mL for the indicated time. 
Molecular Cloning 
 pDEST-HA-FOXM1b, pDEST-Myc-USP21, pDEST-FLAG-FOXM1b, pINDUCER20-
FOXM1b and pINDUCER20 USP21 were all generated using Gateway Cloning Technology 
(ThermoFisher) from pDONR223-FOXM1b and pDONR223-USP21 plasmids. All FOXM1 
fragments described in Figure 3.2 were ordered as synthetic gene fragments (IDT) and 
subsequently cloned into pDONR223 and pDEST-Myc plasmids for expression using Gateway 
Cloning Technology. The FOXM1 6X-DBE luciferase reporter plasmid was a gift from Michael 
Whitfield (Dartmouth University). FLAG-HA-USP21 plasmid was a gift from Wade Harper 
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(Addgene plasmid # 22574) (58). pINDUCER20 was a gift from Stephen Elledge (Addgene 
plasmid # 44012) (260). 6-HIS-FLAG Ubiquitin plasmid was a gift from Philippe Soubeyran. 
Site-directed mutagenesis with QuickChange Lightning Kit (Agilent) was used to generate 
C221A MSCV-FLAG-HA-USP21 following manufacturer’s instructions. Primers used are 
described in Table 3.3. 
Lentivirus Production 
 293T cells were transfected with pINDUCER20 plasmids mixed with VSV-G, Gag-Pol, 
Tat and Rev lentivirus packaging helper plasmids in a 1:4 ratio. Media containing viral particles 
was harvested 24 and 48 hours later, passed through a 0.45µM filter and stored frozen at -80°C. 
MDA-MB-231 cells were transduced with lentiviral particles and selected with G418 to isolate 
successfully transduced cells. 
Immunoblotting 
 Samples were lysed in RIPA buffer (150mM NaCl, 50mM Tris pH 7.5, 5mM EDTA, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1µg/mL aprotinin and 
leupeptin, 10µg/mL leupeptin, 1mM sodium orthovanadate, 1mM NaF, and 1mM AEBSF. Protein 
concentration was quantified by Pierce BCA assay (ThermoFisher) and samples were prepared by 
boiling in Laemmli buffer for 5 minutes. Samples were separated by gel electrophoresis using 
homemade or TGX (Bio-Rad) SDS-PAGE gels and transferred to nitrocellulose membrane. All 
blocking and antibody washing steps were performed in 5% nonfat dried milk (Bio-Rad) diluted 
in TBS-T (137mM NaCl, 2.7mM KCl, 25mM Tris pH 7.4, 1% Tween-20). All primary antibody 
incubations were performed shaking at 4°C for 16 hours. All secondary antibody incubations were 
performed shaking at room temperature for 1 hour. All washing steps were performed using TBS-
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T. Protein abundance was visualized by chemiluminescence using Pierce ECL (ThermoFisher), or 
Clarity ECL (Bio-Rad). A list of all antibodies used in this study are described is Table 3.4. 
Immunoprecipitations 
 293T cells were transfected with the indicated plasmids and lysed in NETN buffer (100mM 
NaCl, 20mM Tris pH 8, 0.5mM EDTA, 0.5% NP-40 supplemented with 1µg/mL aprotinin and 
leupeptin, 10µg/mL leupeptin, 1mM sodium orthovanadate, 1mM NaF, and 1mM AEBSF) 48 
hours after transfection. 1µg of the indicated antibody was conjugated to a 50µl mix of magnetic 
Protein A and Protein G beads (Bio-Rad) at room temperature for 1 hour. 1mg of lysate from each 
sample was pre-cleared to remove non-specific interactions with a similar volume of Protein A/G 
beads rotating at 4°C for 1 hour.  Following antibody conjugation and pre-clearing, lysate and 
beads were combined rotating at 4°C for 4 hours. Beads were subjected to multiple rounds of 
washing with NETN. Proteins were eluted by boiling beads in Laemmli buffer for 10 minutes and 
visualized by IB. 
FOXM1 and USP21 In Vitro Binding Assay 
 FOXM1b was subcloned into a pET-28b backbone to create a C-terminal 6X-Histidine 
tagged clone, transformed into Escherichia coli BL21(DE3) cells, grown to an OD600 of 0.5, and 
induced to express with 250µM of IPTG shaking at 18°C for 16 hours. USP21 was cloned into a 
pDEST15 backbone using Invitrogen Gateway cloning technology (ThermoFisher) to create a N-
terminal GST-tagged clone, transformed into Escherichia coli BL21(DE3) cells, grown to an 
OD600 of 0.5, and induced to express with 100µM of IPTG shaking at 25°C for 5 hours. Bacterial 
pellets were resuspended in 40mL lysis buffer (20mM KH2PO4 pH 7.5, 500mM NaCl, 10% 
glycerol, 2µg/mL aprotinin, 10µg/mL leupeptin, 2µg/mL pepstatin, 1mM sodium orthovanadate, 
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1mM NaF 1mM AEBSF, 10mg/mL lysozyme, 40U DNase I; leupeptin and AEBSF not included 
in GST-USP21 lysis). 6HIS-FOXM1b and GST-USP21 were batch purified from crude lysate on 
His-Pur Ni-NTA resin (ThermoFisher) and glutathione agarose resin (GoldBio) following 
manufacturer’s protocols, respectively. Following elution, proteins were buffer exchanged (25mM 
Tris pH 7.4, 200mM NaCl, 2mM DTT) using Zeba desalting columns (ThermoFisher) following 
manufacturer’s protocols. For interaction studies, 1µg of GST or GST-USP21 was conjugated to 
GSH agarose resin rotating at room temperature for 1 hour. Then, 1µg 6HIS-FOXM1b was added 
and incubation continued with rotation at room temperature for 1 hour. Following three rounds of 
washing with PBS, protein complexes were eluted (50mM Tris pH 8.0, 10mM glutathione), 
resuspended in Laemmli buffer and assessed by IB. 
FOXM1 Transcriptional Reporter Assay 
 293T cells were transfected with FOXM1 6X-DBE luciferase reporter and FLAG-HA-
USP21 plasmids as indicated and collected 24 hours after transfection. Lysates were prepared 
according to the protocol described in the Luciferase Assay System (Promega). Measurements 
were made in a 96-well plate and results represent the average of triplicates for each experiment 
condition described. 
Cell Cycle Progression into Mitosis 
 MDA-MB-231 cells were transfected with the indicated siRNA using RNAiMAX. 48 
hours following transfection, media on cells was refreshed with media containing 2µg/mL 
aphidicolin. 24 hours later, media on cells was refreshed with media containing 200ng/mL 
nocodazole. Cells were harvested at the indicated time points and samples were prepared for IB or 
for flow cytometry by fixation in 70% ethanol. For flow cytometry, cells were blocked for 30 
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minutes, incubated with rabbit anti-phospho-Histone H3 (S10) antibody for 1 hour, then incubated 
with goat anti-rabbit Alexa Fluor 488 for 1 hour, and finally stained with 25µg/mL propidium 
iodide, 100µg/mL RNase A for 1 hour. All blocking, washing, and staining steps were done with 
1% BSA in PBS. All samples were run on a CyAn ADP analyzer (Beckman Coulter) and data was 
analyzed using FlowJo X software. 
In Vitro Paclitaxel Sensitivity Assays 
 MDA-MB-231 pINDUCER20-FOXM1b, MDA-MB-468 and SUM149 cells were 
transfected with the indicated siRNAs. 24 hours following transfection, cells were seeded in 
triplicates at a density of 7,500 cells / well in a 96-well plate. 12 hours after seeding, media 
supplemented with paclitaxel, and in one set of siUSP21 triplicates (MDA-MB-231 pINDUCER20 
FOXM1b only), paclitaxel with 10ng/mL doxycycline was added to cells. After a 72 hour 
incubation, cell viability was assessed using PrestoBlue reagent according to manufacturer’s 
instructions. 
Tumor Xenograft 
 SUM149 cells were transduced with lentivirus expressing shRNA against USP21 or a non-
targeting control and selected of positive expression with puromycin. Immediately following 
selection, orthotopic xenografts were established for all conditions by injecting subcutaneously 5 
x 106 cells mixed 50:50 in serum-free media:matrigel into the right mammary fat pad of athymic, 
female nude mice. Tumor volume was measured with calipers and calculated using the equation 
Volume = Length x Width2 x 0.563. Upon tumors reaching a volume 100mm3, mice were 
administered a bi-weekly intraperitoneal injection of 10mg/kg (body weight) paclitaxel or 
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equivalent volume of vehicle. Tumor volume measurements were recorded twice weekly for 6 
weeks.  
Proliferation Assays 
 MDA-MB-231 pINDUCER20 FOXM1b and MDA-MB-468 cells were transfected with 
the indicated siRNA, then 12 hours later, 30,000 cells/well were seeded into 24-well plates in 
triplicates for each condition. Growth was monitored through phase-contrast imaging using the 
IncuCYTE Zoom (Essen Bioscience) live-cell imaging device. Images were taken every 6 hours 
for 120 total hours and growth was calculated for each timepoint as the average percent confluence 
of 4 images taken per well. Values were normalized for each respective condition so initial 
confluence starts at 0%. 
 HeLa cells were transfected with the indicated siRNA, then 24 hours later, transfected with 
the indicated plasmids. Growth was monitored using PrestoBlue cell viability reagent 
(ThermoFisher) following the manufacturers protocol. Measurements were taken in triplicate for 
each timepoint with each point described as a percentage of the first measurement taken following 
seeding. 
In Vivo Deubiquitination Assay 
The in vivo ubiquitination assay was performed as described previously (247). Briefly, 
293T cells were transfected with the indicated plasmids and harvested in PBS 24 hours following 
transfection. 80% of the cell suspension was lysed in 6M guanidine-HCL buffer and 6HIS-
ubiquitinated proteins were captured on HisPur Ni-NTA resin (ThermoFisher) while the 
remaining 20% of sample was used to prepare inputs. Pull-down eluates and inputs were 
separated on SDS-PAGE gels and analyzed by IB. 
 77 
In Vitro Deubiquitination Assay 
 293T cells were transfected with HA-FOXM1b and 6xHIS-FLAG-ubiquitin and separately 
with FLAG-HA-USP21WT, FLAG-HA-USP21C221A and empty vector, respectively. 48 hours 
following transfection, cells transfected with HA-FOXM1b/6xHIS-FLAG-ubiquitin were treated 
with complete DMEM supplemented with 25µM MG132 for 1 hour prior to harvesting. HA-
FOXM1b/6xHIS-FLAG-ubiquitin cells were lysed in RIPA buffer (150mM NaCl, 50mM Tris pH 
7.5, 5mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 1µg/mL 
aprotinin and leupeptin, 10µg/mL leupeptin, 1mM sodium orthovanadate, 1mM NaF, 1mM 
AEBSF and 20mM NEM. FLAG-HA-USP21WT, FLAG-HA-USP21C221A and empty vector cells 
were lysed in RIPA buffer without additional inhibitors. HA-tagged proteins were captured from 
clarified cell lysate on 50µL EZview Red Anti-HA Affinity Gel (MilliporeSigma) according to 
manufacturer’s instructions. Following capture and washing, beads containing captured HA-
FOXM1b/6xHIS-FLAG-ubiquitin were resuspended in DUB buffer (50mM Tris pH 7.5, 50mM 
NaCl, 5mM DTT, 5mM MgCl2) and mixed equally with beads resuspended in DUB buffer 
containing captured FLAG-HA-USP21WT, FLAG-HA-USP21C221A and empty vector cell lysate. 
Beads were incubated with rotation at 37°C for 4 hours and proteins were eluted directly from 
beads with the addition of Laemlli sample buffer and boiling. Ubiquitination status of HA-
FOXM1b was assessed by IB as described above. 
RT-qPCR 
 MDA-MB-231 cells were transfected with the indicated siRNA and harvested 72 hours 
after transfection. RNA was extracted using RNeasy Mini Kit (Qiagen) following manufacturer’s 
instructions. 1µg of RNA was used to generate cDNA libraries with random primers using 
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SuperScript III Reverse Transcriptase (ThermoFisher) following manufacturer’s instructions. 
Samples were diluted 1:10 and transcript abundance was quantified using SsoAdvanced SYBR 
Green (Bio-Rad) on a QuantStudio 7 Flex Real-Time PCR system (ThermoFisher) normalized to 
GAPDH, with each condition run in triplicates. Data displayed as the relative quantity of 
transcript quantified using the 2−ΔΔCt method (270). All primers used are described in Table 
3.3. 
TCGA Dataset Analysis 
 Upper quartile normalized RSEM gene-level data for 1095 invasive breast cancers were 
downloaded from the legacy TCGA-BRCA project using the NIH Genome Data Commons 
(https://portal.gdc.cancer.gov). Proliferation score was calculated for each sample analyzed as 
previously described (271) and compared to log2-transformed, median-centered FOXM1 
expression data for each sample analyzed. FOXM1 transcriptional targets were log2-
transformed, median-centered and compared to log2-transformed, median-centered FOXM1 
expression. Gene Set Enrichment Analysis (GSEA) (272, 273) was performed for a previously 
derived FOXM1 target gene list (217) comparing USP21-amplified and USP21-non-amplified 
patient tumors. RPPA normalized data was downloaded from the TCGA PanCanAtlas 
Publication page (http://api.gdc.cancer.gov/data/fcbb373e-28d4-4818-92f3-601ede3da5e1) and 
data for 879 breast samples were extracted.  GISTIC values were downloaded from Broad’s 
Firehouse (http://gdac.broadinstitute.org/runs/analyses__2016_01_28/data/BRCA-
TP/20160128/gdac.broadinstitute.org_BRCA-
TP.CopyNumber_Gistic2.Level_4.2016012800.0.0.tar.gz). There were 857 samples with both 
RPPA and copy number data.  GISTIC values of 2 were considered highly amplified for USP21 
and compared to those without high amplification of USP21 for volcano plots and to compare 
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proliferation score. An FDR-corrected Wilcoxon rank sum test was used to calculate proteins 
associated with USP21 copy number status. Data from 505 breast invasive carcinoma samples 
from TCGA (190) were downloaded from cBioPortal (http://www.cbioportal.org/) (274, 275). 
Percent of samples with CNA amplification and mRNA overexpression (Z-score threshold +/- 2) 
of 92 DUBs was aggregated. 
Other Statistical Analysis 
 Analysis of FOXM1 half-life stability was assessed by densitometry of bands on 
immunoblots using ImageJ. Band intensity was calculated for FOXM1 and the respective 
loading control for each lane/timepoint. Non-specific background was subtracted from the signal 
of each band. FOXM1 intensity at a given timepoint was normalized to the amount of loading 
control in that lane. For calculating half-life, all timepoints were calculated as a percentage of 
initial FOXM1 abundance for each respective condition. The best-fit nonlinear regression curve 
was drawn through points and half-life was assed as time when y = 50% using GraphPad Prism 
6. Key details of the statistical analysis pertaining to RT-qPCR, proliferation assays, paclitaxel 
sensitivity assays and tumor xenograft assays are described in the corresponding method details 








Figure 3.1 USP21 binds and regulates FOXM1 abundance. A. HeLa cells treated with vehicle, 2.5, 5 or 10µM 
PR-619 for 8h were analyzed by immunoblot (IB). B. HeLa cells were transfected with a pool of four independent 
small-interfering RNAs (siRNAs) targeting respective DUBs. FOXM1 stability was assessed by IB 72h after 
transfection. C. FOXM1 levels were assessed by IB following transfection of Myc-FOXM1b and FLAG-HA-USP21 
in 293T cells 48h after transfection. D. FLAG-FOXM1b and Myc-USP21 were co-expressed in 293T cells. Protein 
complexes were immunopurified (IP) with anti-Myc and analyzed by IB. E. HA-FOXM1b and Myc-USP21 were 
co-expressed in 293T cells. Lysates were IP with anti-mouse immunoglobulin G (IgG) or anti-HA and analyzed by 
IB. F. Endogenous USP21 was IP from HeLa whole-cell lysates and analyzed by IB. G. Recombinant 6xHIS-
FOXM1b was incubated with recombinant GST-USP21. Complexes were captured on glutathione (GSH) agarose 







Figure 3.2 Analysis of USP21-FOXM1 binding. A. IB confirming USP21 knockdown and FOXM1 expression in 
HeLa cells transfected with multiple individual USP21 siRNAs for 48h. B. HeLa cells stably expressing FLAG-HA-
USP21 WT or FLAG-HA-USP21 mutated to resist siUSP21 were transfected with indicated siRNAs. FOXM1 
levels were assessed by IB 48h after transfection. C. Diagram of FOXM1b fragments assessed for binding with 
USP21. Putative USP21 binding domain indicated by red line. (Fkh = forkhead domain). D. 293T cells were 
transfected with FLAG-HA-USP21 and the indicated Myc-FOXM1b fragments. Cells were lysed and subjected to 
Myc IP. USP21 binding to FOXM1b fragments was assessed by IB. E. 293T cells were transfected with FLAG-HA-
USP21 and the indicated Myc-FOXM1b fragments. Cells were lysed and subjected to FLAG IP. FOXM1b 




















Figure 3.3 USP21 protects FOXM1 from proteasomal degradation. A. HeLa cells were transfected with the 
indicated siRNAs. After 48h, HeLa cells were treated with 10µM MG132 or vehicle for 6h. B. 293T cells 
transfected with the indicated plasmids were lysed under denaturing conditions and subjected to Ni-NTA pulldown. 
The ubiquitination status of FOXM1 in each condition was assessed by IB. C. Top: 293T cells were transfected with 
the indicated plasmids. After 48h, 100ng/mL of cycloheximide was added to the cells and samples were taken every 







Figure 3.4 USP21 controls FOXM1 ubiquitination and half-life. A. Ubiquitinated HA-FOXM1b was IP from 
293T cells that were treated with MG132 prior to lysis. The precipitated HA-FOXM1b was combined with FLAG-
HA-USP21WT or FLAG-HA-USP21C221A IP from separately transfected 293T cells (not treated with MG132). 
Proteins were resuspended in DUB buffer and incubated at 37°C for 4h. Ubiquitination status of FOXM1 in each 
condition was assessed by IB. B. 293T cells transfected with the indicated plasmids were lysed under denaturing 
conditions and subjected to Ni-NTA pulldown. Ubiquitination status of USP21 in each condition was assessed by 
IB. C. Top: IB of MDA-MB-231 treated with 100ng/mL cycloheximide for the indicated times 48h following 
transfection with the indicated siRNAs. Bottom: densitometry analysis performed on corresponding IBs to assess 






Figure 3.5 USP21 affects growth through modulation of the FOXM1 transcriptional network. A. FOXM1 
transcriptional activity was measured by quantifying luciferase activity in 293T cells expressing the 6x-DBE 
FOXM1 luciferase reporter with and without USP21 overexpression. Error bars represent SEM. B. Relative 
abundance of FOXM1 target transcripts was assessed by RT-qPCR following RNA extraction from MDA-MB-231 
cells transfected with the indicated siRNA for 72h. Each condition represents means of triplicates. Error bars 
represent min-max. * = p £ 0.05 based on Student’s t-test performed on DCt values. C. IB of cells used in B. 
showing protein levels of various FOXM1 targets. D. Mitosis was scored by measuring P-H3-positive cells by flow 
cytometry in MDA-MB-231 cells transfected with the indicated siRNA or plasmids following release from 
aphidicolin synchronization at the indicated times. E. Growth was measured as the percentage of confluence in the 
dish every 6h over 120h in MDA-MB-468 (left) and MDA-MB-231 pINDUCER20 FOXM1b cells (right) treated 
with the indicated siRNAs (or 10ng/mL of doxycycline) using the IncuCyte live-cell imaging system. Each point 





Figure 3.6 USP21 regulation of cell cycle and proliferation. A. Left: RT-qPCR analysis of FOXM1 and USP21 
mRNA levels in corresponding samples. Right: IB of MDA-MB-231 pINDUCER20 USP21 cells treated with 
vehicle or 10ng/mL doxycycline for 48h. B. IB of samples from the experiment described in Figure 3.5D. C. Left: 
Proliferation measured with PrestoBlue reagent in HeLa cells transfected with indicated siRNA or plasmids over 4 
days. Each measurement is of triplicates. Error bars represent SEM. * = p £ 0.05 and ** = p £ 0.01 based on paired 







Figure 3.7 Amplification of FOXM1 and USP21 is linked to proliferation in BLBC. A. Top: Log2 median 
FOXM1 expression in TCGA breast cancers compared with proliferation score and subtype. Bottom: Log2 median 
FOXM1 expression and 7 FOXM1 target genes ordered by FOXM1 expression. PAM50 breast cancer subtypes: 
basal-like, red; HER2-enriched, hot pink; luminal A, dark blue; luminal B, light blue; normal-like, green. B. 
Analysis comparing mRNA overexpression (Z score threshold ± 2) and CNA amplification of 92 DUBs in 482 
tumor samples from the TCGA breast invasive carcinoma dataset. C. FOXM1 and USP21 abundance assessed by IB 
in a panel of breast cancer cell lines. Breast cancer subtype denoted by color: normal-like, green; luminal, blue; 
HER2, pink; BLBC, red. D. Volcano plot showing protein expression levels in USP21-amplified patient tumors 






Figure 3.8 USP21 knockdown sensitizes BLBC cells to paclitaxel. A. Relative viability of MDA-MB-231 cells 
(pINDUCER20 FOXM1b transduced) (top), MDA-MB-468 cells (middle) and SUM149 cells (bottom) treated with 
the indicated siRNAs and exposed to the indicated concentration of paclitaxel (and 10ng/mL of doxycycline [Dox] 
in siUSP21 + Dox) for 72h. Each condition represents mean of triplicates. Error bars represent SEM. * = p £ 0.05, 
** = p £ 0.01, *** = p £ 0.001 and **** = p £ 0.0001 based on two-way ANOVA with post-hoc pairwise analysis. 
IB confirming expression of FOXM1 and USP21 is shown to the right for each corresponding experiment. B. 
Quantification of mean tumor volume of SUM149 mouse xenograft for the indicated conditions. Error bars represent 





Figure 3.9 Analysis of USP21 and proliferation in breast cancer. A. Proliferation score of TCGA breast cancers 
sorted by USP21. GISTIC scores and PAM50 breast cancer subtypes: basal-like, red; HER2-enriched, hot pink; 
luminal A, dark blue; luminal B, light blue; normal-like, green. B. Comparing relative levels of FOXM1 and USP21 
between BLBC cell lines used throughout the study. C. IB of shRNA transduced SUM149 cells used in mouse 



















Figure 3.10 Illustration of proposed FOXM1-USP21 axis in cell cycle and disease. Under conditions where 
USP21 is overexpressed (right), FOXM1 is more protected from ubiquitin-dependent proteasomal degradation. This 
enhanced protection leads to enhanced FOXM1 stability which contributes to cell cycle progression which drives 
tumor growth and resistance to paclitaxel, based on mechanisms which are regulated by FOXM1. Conversely, 
knockdown of USP21 enhances the ubiquitin-dependent proteasomal degradation of FOXM1. Enhanced FOXM1 
degradation leads to a delayed cell cycle (with cells proceeding slowly through the G2/M cell cycle transition), 




Gene Symbol Description 
Enrichment 
Score Enriched? Gene Symbol 
null null 0.020818 Yes null 
GBA 
glucosidase, beta; acid 
(includes 




32 family, member E 0.061532 Yes ANP32E 
CDCA2 
cell division cycle 
associated 2 0.076739 Yes CDCA2 
KIF14 kinesin family member 14 0.086463 Yes KIF14 
FAM64A 
family with sequence 
similarity 64, member A 0.101637 Yes FAM64A 
NEK2 
NIMA (never in mitosis 
gene a)-related kinase 2 0.112635 Yes NEK2 
CENPF 
centromere protein F, 
350/400ka (mitosin) 0.127031 Yes CENPF 
null null 0.137598 Yes null 
TAF5 
TAF5 RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor, 
100kDa 0.150960 Yes TAF5 
null null 0.163863 Yes null 
CNIH4 
cornichon homolog 4 
(Drosophila) 0.176389 Yes CNIH4 
TTK TTK protein kinase 0.189483 Yes TTK 
RFWD3 
ring finger and WD repeat 
domain 3 0.200674 Yes RFWD3 
AURKB aurora kinase B 0.213545 Yes AURKB 
KIF23 kinesin family member 23 0.224606 Yes KIF23 
KIF20A 
kinesin family member 




(Xenopus laevis) 0.247021 Yes TPX2 
PLK1 
polo-like kinase 1 
(Drosophila) 0.258741 Yes PLK1 
CCNA2 cyclin A2 0.270580 Yes CCNA2 
CENPA centromere protein A 0.282854 Yes CENPA 
ASPM 
asp (abnormal spindle) 
homolog, microcephaly 
associated (Drosophila) 0.292733 Yes ASPM 
UBE2C 
ubiquitin-conjugating 
enzyme E2C 0.304951 Yes UBE2C 
NCAPD2 
non-SMC condensin I 
complex, subunit D2 0.314267 Yes NCAPD2 
FAM83D 
family with sequence 
similarity 83, member D 0.325644 Yes FAM83D 
CDCA8 
cell division cycle 
associated 8 0.337109 Yes CDCA8 
CDC20 
CDC20 cell division cycle 
20 homolog (S. 
cerevisiae) 0.342095 Yes CDC20 
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NUCKS1 
nuclear casein kinase and 
cyclin-dependent kinase 
substrate 1 0.351519 Yes NUCKS1 
CCNB1 cyclin B1 0.361443 Yes CCNB1 
null null 0.369896 Yes null 
CKAP2L 
cytoskeleton associated 
protein 2-like 0.380350 Yes CKAP2L 
CHEK2 
CHK2 checkpoint 
homolog (S. pombe) 0.390651 Yes CHEK2 
CCNB2 cyclin B2 0.400656 Yes CCNB2 
null null 0.410612 Yes null 
null null 0.419783 Yes null 
KIF11 kinesin family member 11 0.430068 Yes KIF11 
KIF2C kinesin family member 2C 0.440508 Yes KIF2C 
PTTG1 
pituitary tumor-






associated) 0.452136 Yes SFPQ 
LMNB1 lamin B1 0.461743 Yes LMNB1 
HN1 
hematological and 
neurological expressed 1 0.471860 Yes HN1 




delta) 0.489990 Yes CALM2 
ZBTB5 
zinc finger and BTB 
domain containing 5 0.496343 Yes ZBTB5 
DEPDC1 DEP domain containing 1 0.506175 Yes DEPDC1 
H2AFZ 
H2A histone family, 
member Z 0.510321 Yes H2AFZ 
NAV2 neuron navigator 2 0.518510 Yes NAV2 
SPAG5 
sperm associated antigen 
5 0.523995 Yes SPAG5 
AURKA aurora kinase A 0.525815 Yes AURKA 
RACGAP1 
Rac GTPase activating 
protein 1 0.534634 Yes RACGAP1 
null null 0.539924 Yes null 
ARHGAP11A 
Rho GTPase activating 
protein 11A 0.543528 Yes ARHGAP11A 
ESPL1 
extra spindle poles like 1 
(S. cerevisiae) 0.551075 Yes ESPL1 
INCENP 
inner centromere protein 
antigens 135/155kDa 0.554538 Yes INCENP 
UBE2S 
ubiquitin-conjugating 
enzyme E2S 0.559898 Yes UBE2S 
KPNA2 
karyopherin alpha 2 (RAG 
cohort 1, importin alpha 
1) 0.567097 Yes KPNA2 
CKAP2 
cytoskeleton associated 
protein 2 0.572269 Yes CKAP2 
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NUSAP1 
nucleolar and spindle 




(RHAMM) 0.585622 Yes HMMR 
C15ORF23 
chromosome 15 open 
reading frame 23 0.592526 Yes C15ORF23 
HMGB2 high-mobility group box 2 0.600037 Yes HMGB2 
null null 0.605212 Yes null 
PRC1 
protein regulator of 
cytokinesis 1 0.612895 Yes PRC1 
KIF18A 
kinesin family member 




associated dual specificity 




(isopeptidase T-3) 0.627647 Yes USP13 
FBXO5 F-box protein 5 0.633751 Yes FBXO5 
PHF19 PHD finger protein 19 0.639432 Yes PHF19 
FAM100B 
family with sequence 




21) 0.641250 Yes CIT 
ARHGAP11B 
Rho GTPase activating 
protein 11B 0.645701 Yes ARHGAP11B 
ZNF165 zinc finger protein 165 0.652198 Yes ZNF165 
null null 0.658336 Yes null 
BTN2A1 
butyrophilin, subfamily 2, 
member A1 0.657704 Yes BTN2A1 
ATAD2 
ATPase family, AAA 
domain containing 2 0.654522 Yes ATAD2 
null null 0.656237 Yes null 
ECT2 
epithelial cell transforming 
sequence 2 oncogene 0.655710 Yes ECT2 
CKAP5 
cytoskeleton associated 
protein 5 0.659738 Yes CKAP5 
ASXL1 
additional sex combs like 
1 (Drosophila) 0.663116 Yes ASXL1 
CDKN2D 
cyclin-dependent kinase 
inhibitor 2D (p19, inhibits 
CDK4) 0.668286 Yes CDKN2D 
TUBB2C tubulin, beta 2C 0.673261 Yes TUBB2C 
TOP2A 
topoisomerase (DNA) II 
alpha 170kDa 0.676790 Yes TOP2A 
QSER1 
glutamine and serine rich 
1 0.668105 No QSER1 
SVIL supervillin 0.613905 No SVIL 
CEP192 
centrosomal protein 
192kDa 0.612476 No CEP192 
PPP1R10 
protein phosphatase 1, 
regulatory subunit 10 0.596670 No PPP1R10 
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FNBP4 formin binding protein 4 0.589752 No FNBP4 
PTMS parathymosin 0.592817 No PTMS 
MAD2L1BP MAD2L1 binding protein 0.590704 No MAD2L1BP 
TTF2 
transcription termination 
factor, RNA polymerase II 0.573532 No TTF2 
H2AFX 
H2A histone family, 
member X 0.564126 No H2AFX 
FZR1 
fizzy/cell division cycle 20 
related 1 (Drosophila) 0.531594 No FZR1 
null null 0.500078 No null 
CEP110 
centrosomal protein 
110kDa 0.432021 No CEP110 
SMAD6 
SMAD, mothers against 
DPP homolog 6 
(Drosophila) 0.379289 No SMAD6 
KRAS 
v-Ki-ras2 Kirsten rat 
sarcoma viral oncogene 
homolog 0.379367 No KRAS 
null null 0.337533 No null 
null null 0.322027 No null 
RNF26 ring finger protein 26 0.309723 No RNF26 
WEE1 
WEE1 homolog (S. 
pombe) 0.307540 No WEE1 
STK17A 
serine/threonine kinase 
17a (apoptosis-inducing) 0.302677 No STK17A 
PPM1B 
protein phosphatase 1B 
(formerly 2C), 
magnesium-dependent, 
beta isoform 0.300841 No PPM1B 
KBTBD2 
kelch repeat and BTB 
(POZ) domain containing 
2 0.300771 No KBTBD2 
HIST1H2AG histone cluster 1, H2ag 0.288100 No HIST1H2AG 
APOLD1 
apolipoprotein L domain 
containing 1 0.282930 No APOLD1 
null null 0.219432 No null 
null null 0.137236 No null 
null null 0.121622 No null 
ZNF785 zinc finger protein 785 0.074998 No ZNF785 
DZIP3 - 0.071994 No DZIP3 
DHRS7B 
dehydrogenase/reductase 
(SDR family) member 7B 0.057230 No DHRS7B 
SMAD3 
SMAD, mothers against 
DPP homolog 3 
(Drosophila) 0.010142 No SMAD3 
null null -0.009193 No null 
null null 0.000685 No null 
 
Table 3.1 FOXM1 target gene enrichment correlated to USP21 amplification. Gene Set Enrichment Analysis 
(GSEA) was performed for a previously derived FOXM1 target gene list comparing USP21-amplified and USP21-
non-amplified patient tumors. 
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shNonT CAACAAGATGAAGAGCACCAA pLKO.1 backbone





Note: All siRNA have [dT][dT] overhang. All siRNA were used pooled unless otherwise noted.
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Primer Name Sequence (5' - 3') Notes
AURKA qPCR GAGGTCCAAAACGTGTTCTCG Fwd
ACAGGATGAGGTACACTGGTTG Rev
CCNB1 qPCR TTCCAGTTATGCAGCACCT Fwd
ACTTGTTCTTGACAGTCATGTG Rev
CDK1 qPCR GGTTCCTAGTACTGCAATTCG Fwd
AGCACATCCTGAAGACTGAC Rev
FOXM1 qPCR CGTGGATTGAGGACCACTTT Fwd
GGCTTAAACACCTGGTCCAA Rev
GAPDH qPCR GGCCTCCAAGGAGTAAGACC Fwd
AGGGGTCTACATGGCAACTG Rev
PLK1 qPCR GACAAGTACGGCCTTGGGTA Fwd
GTGCCGTCACGCTCTATGTA Rev












USP21 Catalytically Dead SDM
USP21 siRNA Resistant SDM
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Antibody Company/Product # Species
Aurora A CST / 3092 Rabbit
Anti-Mouse IgG (H+L) HRP Jackson ImmunoResearch / 115-035-003 Goat
Anti-Mouse IgG (L) HRP Jackson ImmunoResearch / 115-035-174 Goat
Anti-Rabbit IgG (H+L) Alexa Fluor 488 Thermo Fisher / A-11034 Goat
Anti-Rabbit IgG (H+L) HRP Jackson ImmunoResearch / 111-035-003 Goat
Anti-Rabbit IgG (L) HRP Jackson ImmunoResearch / 211-032-171 Mouse
CCP110 Bethyl / A301-343A Rabbit
CDK1 Bethyl / A303-663A Rabbit
Cyclin B1 Abcam / ab32053 Rabbit
Cyclin E1 CST / 4129 Mouse
FLAG M2 Sigma-Aldrich / F1804 Mouse
FOXM1 Santa Cruz / sc-502 Rabbit
GAPDH Santa Cruz / sc-25778 Rabbit
GST Gene Tex / GTX114099 Rabbit
HA BioLegend/Covance  / MMS-101P Mouse
Myc Santa Cruz / sc-40 Mouse
Normal Mouse IgG Santa Cruz / sc-2025 Mouse
Phospho-Histone H3 S10 CST / 3377 Rabbit
Tubulin Santa Cruz / sc-32293 Mouse
USP21 Rabbit
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
 At its core, the cell cycle is orchestrated by a series of molecular steps that must be 
carried out in an ordered and timely fashion. The transcription of genes necessary to create the 
proteins that will allow the cell to proceed from one step of the growth cycle to the next at the 
right time is essential. Also necessary is the destruction of proteins that either serve to restrain 
the cell cycle when the time is right to push forward or that were once needed to satisfy the 
growth requirements for one stage but are no longer needed for the next phase. The UPS 
oversees this fundamental process and also serves to activate and fine-tune myriad signaling 
pathways in a multitude of ways that we are still uncovering. Taken broadly, these two pathways, 
transcriptional activation and ubiquitin-dependent destruction, are intimately linked together. By 
understanding all of the connections between these two pathways we can shed light on the 
molecular network of events that allow us to develop and grow, and also better understand the 
diseases that result when these networks become dysregulated. 
 The previous chapters focus on FOXM1, one transcription factor that is a master 
transcriptional regulator of the cell cycle. Its importance in both normal cell cycle regulation and 
the promotion of a variety of cancers is well documented. Though a great deal is known about 
the interactions with various kinases and phosphatases that regulate FOXM1 through the addition 
and removal of phosphorylation, respectively, much less was known about its regulation through 
ubiquitin-dependent mechanisms. The work presented here extends our knowledge of how the 
UPS regulates FOXM1 and as a result, regulates cell cycle transcription.  
 In Chapter 2, experiments are described that identify FOXM1 as a substrate of the E3 
ubiquitin ligase CUL4VPRBP. CUL4VPRBP is able to bind to FOXM1, adding polyubiquitin chains 
that lead to FOXM1 proteasomal degradation primarily during S-phase. Knockdown of VPRBP 
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is sufficient to increase the stability of FOXM1. Interestingly, ectopic overexpression of VPRPB 
seems to activate the transcriptional activity of FOXM1, a process which seems to occur 
independent of the association of VPRBP with the CUL4 scaffold. Furthermore, The FOXM1-
CUL4VPRBP axis seems to be upregulated in high-grade serous ovarian cancer, where the FOXM1 
network of genes is highly activated. The activation of FOXM1 by VPRBP may in part explain 
why the FOXM1 transcriptional network is so amplified in ovarian cancer despite the fact that 
FOXM1 protein and mRNA is not highly expressed in this type of cancer. Taken together, these 
studies unveil a new link between the UPS and cell cycle transcription which demonstrates the 
complex role that ubiquitin can play as both a degradative and an activating post-translational 
modification and how looking at the influence of the UPS on transcriptional control may explain 
how transcriptional networks can be upregulated in spite of obvious mechanistic explanation. 
 In Chapter 3, the experiments identify and characterize FOXM1 as a substrate of the 
DUB USP21. The experiments demonstrate that USP21 is able to directly bind and remove 
polyubiquitin chains from FOXM1. As such, USP21 overexpression is sufficient to enhance the 
stability of FOXM1 by protecting it from proteasomal degradation and the knockdown of USP21 
is sufficient to destabilize FOXM1 by promoting its proteasomal degradation. Through this 
action, USP21 levels are able to influence the broader FOXM1 transcriptional network through 
its effect on FOXM1. The FOXM1 is able to influence mitotic progression, which more broadly 
influences cell growth and proliferation. To that point, USP21 knockdown is able to slow both 
cell cycle progression through mitosis and cell growth in a FOXM1-dependent manner. 
Intriguingly, both the expression of USP21, FOXM1 and numerous FOXM1 transcriptional 
targets are significantly higher in basal-like breast cancer, a particularly aggressive subtype of 
breast cancer with few treatment options and through which the upregulation of the FOXM1 
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transcriptional network is believed to contribute significantly to disease progression. 
Intriguingly, the USP21 gene is located on chromosome 1q23, a region that is focally amplified 
in the vast majority of basal-like breast cancers, but to which a clear oncogene has yet to be 
attributed (85). Finally, the clinical implications that USP21 knockdown may have on sensitizing 
basal-like breast cancer to the frontline chemotherapy paclitaxel is investigated. No targeted 
treatment options are available for aggressive basal-like breast cancers and furthermore, FOXM1 
overexpression is linked to paclitaxel resistance (195). In both cell culture and mouse xenograft 
models, it was demonstrated that USP21 knockdown is able to sensitize cells to paclitaxel in a 
FOXM1-dependent manner. Furthermore, this was demonstrated in a cell line SUM149, that is 
resistant to clinically-relevant concentrations of paclitaxel. Taken together, this study not only 
describes one mechanism which the UPS works to promote the stability of FOXM through the 
activity of USP21, but also sheds insight into a possible interaction which may be relevant to the 
promotion of basal-like breast cancer and might also be an avenue of therapeutic intervention to 
treat the disease clinically. 
 There are a number of implications and future directions branching off from this research. 
One area of inquiry that should be explored is the molecular nature of the Vpr-induced G2/M 
arrest that occurs following HIV infection. VPRBP is named for its known association with the 
HIV viral accessory protein Vpr, which engages with CUL4VPRBP to degrade a number of host 
proteins (36–38, 40). Though it is well established that a G2/M arrest follows a productive HIV 
infection, and that this arrest hinges on Vpr association with VPRBP, the molecular reason for 
this remains incomplete (43–47). The research described in Chapter 2 demonstrates that 
FOXM1, the master transcriptional regulator of mitosis, is bound and ubiquitylated by 
CUL4VPRBP. It is intriguing to think that enhanced degradation of FOXM1 through Vpr 
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associating with CUL4VPRBP is the key molecular event that arrests cells in G2/M during HIV 
infection. It is well established and confirmed by studies in Chapter 3 that FOXM1 knockdown is 
sufficient to arrest cells in G2. Future work should explore this explanation within the context of 
HIV infection in relevant T-cell lineages. 
 Another intriguing line of inquiry lies in understanding how changes to the epigenetic 
landscape mediated by VPRBP and USP21 change FOXM1-dependent transcriptional activity. 
In addition to its role as a ubiquitin ligase, it was discovered that the N-terminal of VPRBP 
contains a cryptic kinase domain which is able to regulate phosphorylation on histone H2AT120 
(276). This post-translational modification is tied to regulating transcriptional activity. 
Additionally, recent work demonstrated that H2AT120 phosphorylation and H2AK119 
ubiquitination are antagonistic post-translational modifications that compete to influence 
transcriptional activity of genes such as CCND1, which intriguingly, is a well-characterized 
FOXM1 transcriptional target (277). Even more intriguing is that the removal of transcriptionally 
repressive ubiquitin from H2AK119 is mediated by USP21 (73, 277). As such, there is a lot of 
connectedness between FOXM1, VPRBP and USP21 that converge at this level. The model 
suggested by Aihara et al. proposes that phosphorylation on H2AT120 helps to activate genes 
whereas ubiquitination on H2AK119 is associated with the repression of active transcription. 
The research presented here is compatible with this model in which both VPRBP has been 
shown to activate FOXM1 and localize to FOXM1 target promoters and that USP21 also 
promotes the transcription of FOXM1 target genes. Perhaps both USP21 and VPRBP are 
necessary to sculpt the histone landscape to promote active transcription of a number of targets 
in addition to their activity in stabilizing FOXM1 and promoting its transcriptional activity 
respectively. Future work should study what is happening with these histone modifications when 
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VPRBP and USP21 levels are altered and what result this has on localizing FOXM1 to target 
promoters and on FOXM1 target transcription. Additionally, it should be explored if VPRBP-
dependent phosphorylation is in any way needed for the activation of FOXM1 as it is well 
established that phosphorylation is needed to fully activate FOXM1. Furthermore, it should be 
explored if USP21 is also targeted to FOXM1 target promoters much like VPRBP is. This would 
be compatible with the proposed model from Aihara et al. and also compatible with research that 
suggests that FOXM1 binding to transcriptional coactivators is very important in dictating its 
localization to various target gene promoters.  
 Future work should better characterize the specific amino acids recognized by USP21 on 
FOXM1. While we do have recognition motifs for many classes of enzymes which confer post-
translational modifications on substrates, there are few rules dictating substrate recognition by 
DUBs. The interaction domain on FOXM1 recognized by USP21 was narrowed down to a 79 
amino acids region on FOXM1 which contained a large portion of the Forkhead box motif. 
Considering VPRBP binding to FOXM1 was dependent on this region as well and was shown to 
be highly dependent on residues 418, 419 and 422, it would be interesting to determine if these 
regions also affected USP21 binding or influence on FOXM1 ubiquitination status. This would 
tie USP21 and VPRBP closer together in the control of FOXM1 stability. 
 There are still many specific questions remaining surrounding how the interaction 
between FOXM1 and USP21 is regulated. It is still unclear if there is a particular time in the cell 
cycle where the USP21-FOXM1 interaction is more productive. It is also unclear what role 
phosphorylation has to play in this interaction. The results from the ectopic co-IP studies are 
suggestive that phosphorylated FOXM1 is a stronger interactor with USP21 (Figure 3.1D), but it 
remains true that these proteins are able to interact without phosphorylation modifying either 
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protein (Figure 3.1G). USP21 is known to be phosphorylated itself, but it is unclear what role 
this plays in enhancing or repressing USP21 activity. 
 In light of the findings which implicate FOXM1 as an essential piece of the Wnt/b-
catenin signaling cascade, it is interesting to speculate how USP21 fits into this model (169). 
Indeed, a genome wide screen of DUBs involved in potentiating Wnt/b-catenin signaling 
demonstrated that USP21 is the second most potent activator or inhibitor of signaling with 
overexpression and knockdown, respectively (278). The molecular details of this observation 
were not interrogated more deeply. It is interesting to speculate that the stabilization of FOXM1 
in a USP21-dependent manner is at work here. It is also interesting to speculate that the FOXM1-
USP21 interaction is enhanced by Wnt signaling, as has been demonstrated by the interaction 
between FOXM1 and USP5 (183). 
 Additional experiments should be done to address the role that USP21 has in mediating 
the effects of paclitaxel through direct association with centrosomes and microtubules. In 
Chapter 3 it is demonstrated that USP21 knockdown can sensitize cells to the microtubule poison 
paclitaxel. Though this effect is mostly rescued by forced FOXM1 overexpression, it is not 
entirely rescued. Various groups have reported that USP21 is an important regulator of 
centrosome and microtubule-associated functions (71). The functions that USP21 has directly on 
the centrosome or on microtubules combined with paclitaxel remain completely unexplored and 
may prove insightful in fully understanding the observed sensitization that USP21 knockdown 
confers. 
 The finding that the FOXM1-USP21 interaction seems to enhance basal-like breast 
cancer growth and treatment sensitivity should be explored in additional cancer models. Bladder 
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cancer is particularly interesting due to the molecular similarities to basal-like breast cancer and 
the high degree of USP21 expression in the disease. Additionally, there are two common 
mutations in the USP domain of USP21 at R441 and S476 that occur across cancer types (279). 
It would be interesting to dissect what effect these mutations had on USP21 substrate 
ubiquitination given that USP21 amplification seems to be associated with cancer. 
 Finally, a more complete catalog of USP21 substrates identified by mass spectrometry 
would be beneficial. Studies have been performed to broadly identify substrates of USP21 by IP-
MS/MS (58), but I believe the lysis techniques utilized to analyze substrates by IP miss a large 
portion of the available substrates as many nuclear and chromatin interacting substrates are likely 
removed from analysis. The application of diGly (280) proteomics with DUB knockdown and 
overexpression to capture broad changes to protein ubiquitination has the potential to discover 
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